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Abstract-Open	
	
INTRODUCTION:		
Critical	to	the	management	of	pulmonary	atresia	(PA)	or	pulmonary	stenosis	(PS)	is	
accurate	and	comprehensive	knowledge	of	the	vascular	network	supplying	the	lungs.	This	
vascular	network	can	be	exceedingly	complex	as	it	may	include	a	wide	variation	of	
systemic	to	pulmonary	collateral	arteries	(SPC/s).			
	
AIM:		
This	study	aims	to	guide	radiologists,	cardiologists	and	cardiothoracic	surgeons	in	their	
search	for	SPC/s	and	to	recommend	an	accurate,	informative	and	standardised	
nomenclature	system	for	SPC/s	based	on	the	relative	frequency	of	SPC/s	origins	in	
patients	with	PA	or	PS	identified	using	multi-detector	computed	tomography	
arteriography	(MDCTA).	
	
METHOD:		
In	this	retrospective	descriptive	study	a	data	set	was	created	incorporating	MDCTA	cases	
performed	at	Red	Cross	War	Memorial	Children’s	Hospital,	Cape	Town,	South	Africa	
(RCWMCH)	during	the	period	November	2013	to	November	2017.	Using	multiple,	
temporally	separated	readers,	cases	with	PA	or	PS	were	identified	and	further	analysed	
for	systemic	to	pulmonary	circulation	collateral	supply,	including	patent	ductus	arteriosus	
(PDA)	and	SPC/s	with	special	attention	given	to	their	origins	and	destinations.	
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RESULTS:		
Of	145	eligible	MDCTAs,	93	demonstrated	PA	or	PS	of	which	31	demonstrated	systemic	to	
pulmonary	circulation	collateral	supply,	17	with	a	PDA,	19	with	a	single	SPC/s,	5	with	both	
a	PDA	and	SPC/s	and	14	with	multiple	SPC/s.	The	majority	of	SPC/s	originated	from	the	
descending	aorta,	however,	there	were	numerous	other	intra-	and	extrathoracic	systemic	
arterial	vessels	of	origin.		
	
CONCLUSIONS:		
The	recommended	systematic	search	pattern	for	systemic	to	pulmonary	circulation	
collateral	supply	as	determined	by	their	relative	frequencies	of	origin	should	be	for	a	PDA	
first,	then	for	SPC/s	originating	from	the	descending	aorta	(DA),	aortic	arch	(AArch),	left	
subclavian	artery	(LSCA)	and	right	subclavian	artery	(RSCA).	However,	SPC/s	may	arise	
from	numerous	other	sources	and	no	systemic	artery	can	be	neglected.	
	
“Systemic	to	pulmonary	collateral	artery/s”	(SPC/s)	is	a	more	accurate	general	term	than	
“major	aortopulmonary	artery/s”	(MAPCA/s),	as	40%	of	SPC/s	do	not	originate	from	the	
aorta.	The	large	variability	in	location	of	SPC/s	makes	a	classification	system	impractical	
and	favours	descriptive	characterization,	the	simplest	form	of	which	must	include	the	
origin	and	destination	of	each	SPC/s,	for	example	(DA	to	Left	main	pulmonary	artery	
(LMPA))	or	(AArch	to	right	main	pulmonary	artery	(RMPA)).	
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1.	Rationale	
	
Critical	to	the	management	of	pulmonary	atresia	(PA)	“absence	or	closure	of	a	natural	
passage	of	the	body”	(Merriam-Webster,	1986)	and	variable	degrees	of	pulmonary	
stenosis	(PS)	“a	narrowing	or	constriction	of	the	diameter	of	a	bodily	passage	or	orifice”	
(Merriam-Webster,	1986)	is	accurate	and	comprehensive	knowledge	of	the	prevailing	
pulmonary	vasculature,	including	aberrations	of	the	normal	anatomical	supply	and	
collateral	vascular	pathways.	This	vascular	network	can	be	exceedingly	complex	as	it	may	
include	a	wide	variation	of	systemic	to	pulmonary	collateral	arteries	(SPC/s).	Establishing	
the	relative	prevalence	of	different	SPC/s	origins	will	aid	in	developing	a	systematic	search	
pattern	for	identifying	SPC/s.	This	is	of	particular	value	to	the	involved	diagnostic	
radiologist,	cardiologist	and	cardiothoracic	surgeon	when	performing	and	interpreting	
multi-detector	computed	tomography	angiography	(MDCTA)	and	angiographic	studies	in	
the	pre-operative	evaluation	of	PA/PS.		Missed	SPC/s	may	result	in	a	persistent	left	to	
right	shunt	with	progression	to	pulmonary	hypertension,	cor	pulmonale	and	
cardiopulmonary	failure.	Patients	are	also	at	a	higher	risk	of	developing	pulmonary	
emboli	and	dysrhythmias.			
Knowing	the	relative	prevalence	of	different	systemic	to	pulmonary	collateral	artery	
origins	may	also	help	to	develop	a	standardised	nomenclature	system	facilitating	the	
accurate	conveyance	of	information.	Currently,	the	commonly	used	term	for	a	systemic	to	
pulmonary	collateral	artery	is	a	“major	aortopulmonary	collateral	artery/s”		(MAPCA/s).	
This	term	has	likely	developed	as	the	aorta	is	a	frequent	origin	for	systemic	to	pulmonary	
collateral	arteries.	The	term	MAPCA/s,	however,	may	be	a	misnomer	when	the	systemic	
to	pulmonary	collateral	artery	derives	its	origin	from	an	artery	other	than	the	aorta,	
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known	to	include	paramediastinal,	bronchial	and	intercostal	arteries.	Furthermore,	while	
performing	the	same	function	as	a	systemic	to	pulmonary	collateral	artery,	a	patent	
ductus	arteriosus	(PDA)	is	given	special	regard	because	of	its	unique	role	during	
cardiogenesis	and	the	early	postnatal	period.			
	
2.	Introduction	–	Understanding	Pulmonary	Atresia	and	Stenosis,	
Commonly	Related	Imaging	Techniques	and	This	Study	in	Context	
2.1.	Basic	Embryology	of	the	Heart,	Pulmonary	Trunk	and	Main	Pulmonary	Arteries	
2.1.1	Heart	
Blood	islands	develop	in	the	visceral	layer	of	the	lateral	plate	mesoderm.	These	blood	
islands	become	the	primordial	cardiovascular	system,	of	which	the	endocardial	tubes	are	
a	component.	The	endocardial	tubes	fuse	to	form	the	primordial	heart	and	are	
subsequently	surrounded	by	a	loose,	space	holding	tissue	called	cardiac	jelly.		
Myocardium	grows	around	this	cardiac	jelly,	which	spatially	allows	the	myocardium	to	
develop	inward	and	the	now	single	lumen	fused	endocardial	tubes	to	expand	outward.	
The	primordial	heart	differentiates	in	a	bulbous	linear	manner	into	the	sinus	venosus	
(which	receives	blood	from	the	primordial	veins),	primordial	atrium,	primordial	ventricle,	
bulbus	cordis	and	aortic	sac	(from	which	the	1st	aortic	arch	is	originating	and	the	
subsequent	aortic	arches	will	originate).		
The	sinus	venosus	develops	into	the	right	atrium,	vena	cava	and	coronary	sinus;	the	
primordial	atrium	develops	into	the	left	atrium	and	right	and	left	atrial	auricles;	and	the	
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primordial	ventricle	develops	into	the	left	ventricle.	The	bulbus	cordis	is	more	
complicated	as	it	includes	the	conus	cordis	and	the	truncus	arteriosus.	The	proximal	third	
of	the	bulbus	cordis	develops	into	the	muscular	right	ventricle;	the	conus	cordis	develops	
into	the	smooth	outflow	tracts	of	the	right	and	left	ventricles;	and	the	truncus	arteriosus	
divides	into	the	proximal	ascending	aorta	and	proximal	pulmonary	trunk.	The	aortic	sac	
develops	into	the	remainder	of	the	ascending	aorta,	most	of	the	aortic	arch	and	the	
brachiocephalic	trunk,	as	well	as	the	remainder	of	the	pulmonary	trunk	(Sadler	&	
Langman,	2010);		(Moorman	&	Christoffels,	2003).	
2.1.2	Partitioning	of	the	Conus	Cordis	and	Truncus	Arteriosus	to	form	the	
Outflow	Tracts,	Aorta	and	Pulmonary	Trunk	
The	primitive	heart	has	a	common	atrioventricular	canal	and	a	common	outflow	tract	
formed	by	the	conus	cordis	and	the	truncus	arteriosus.	Subsequently	the	atria	begin	to	
separate	and	the	interventricular	septum	starts	to	develop	in	such	a	manner	that	the	
common	atrioventricular	canal	and	the	common	outflow	tract	straddle	the	
interventricular	septum.	Two	cell	conglomerates	known	as	endocardial	cushions	grow	to	
separate	the	common	atrioventricular	canal	into	right	and	left	atrioventricular	canals,	
which	correspond	with	the	right	and	left	ventricles.	The	endocardial	cushions	also	go	on	
to	form	the	atrioventricular,	aortic	and	pulmonary	valves.	The	membranous	portion	of	
the	interventricular	septum	extends	downward	to	meet	the	muscular	portion,	known	at	
this	stage	as	the	septum	inferius.		
Simultaneously	to	all	of	these	changes,	the	common	outflow	tract	is	being	divided	by	the	
growth	of	four	staggered	swellings	that	fuse	to	form	a	spiralling	aorticopulmonary	
septum.		
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The	cells	of	the	endocardial	cushions	and	those	of	the	aorticopulmonary	septum	are	from	
the	same	neural	crest	cell	lineage.	They	merge	to	complete	the	separation	of	the	right	
ventricle	and	the	now	anteriorly	located	pulmonary	trunk	from	the	left	ventricle	and	the	
posteriorly	located	aorta.	This	arrangement	is	made	possible	by	the	spiralling	
configuration	of	the	aorticopulmonary	septum	(Sadler	&	Langman,	2010);	(Moorman	&	
Christoffels,	2003).	
2.1.3.	Main	Pulmonary	Arteries	
During	embryological	development	of	the	cardiovascular	system	there	are	6	sets	of	
primitive	aortic	arches.	
The	1st	and	2nd	arches	regress;	the	3rd	arches	form	the	left	and	right	common	and	internal	
carotid	arteries;	the	right	4th	arch	forms	part	of	the	right	subclavian	artery	and	the	left	4th	
arch	forms	part	of	the	aortic	arch;	the	5th	arches	do	not	exist	or	regress	very	early	in	
development;	the	right	6th	arch	forms	the	right	pulmonary	artery	and	the	left	6th	arch	
forms	the	left	pulmonary	artery	and	ductus	arteriosus/ligamentum	arteriosum.		
The	6th	arches	send	branches	into	the	developing	lung	buds,	which	enlarge	to	become	
the	pulmonary	arteries.	As	the	lungs	are	receiving	their	blood	supply,	partitioning	of	the	
conus	cordis	and	truncus	arteriosus	into	the	aorta	and	pulmonary	trunk	begins	to	occur.	
On	the	right	the	communication	between	the	6th	arch	and	the	right	dorsal	aorta	
regresses,	leaving	only	the	right	pulmonary	artery.	On	the	left,	however,	the	
communication	between	the	6th	arch	and	the	left	dorsal	aorta	is	retained	as	the	ductus	
arteriosus	(Sadler	&	Langman,	2010);	(Moorman	&	Christoffels,	2003).		
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2.1.4	Pulmonary	Valve	
As	mentioned	the	cells	of	the	endocardial	cushions	also	go	on	to	form	the	
atrioventricular,	aortic	and	pulmonary	valves	(Sadler	&	Langman,	2010);	(Moorman	&	
Christoffels,	2003).	The	pulmonary	valve	is	located	at	the	base	of	the	pulmonary	trunk	
and	consists	of	three	semilunar	leaflets	created	by	endocardial	folds	in	continuity	with	the	
cardiac	skeleton.	(Gross	&	Kugel,	1931).	When	the	pulmonary	valve	has	conventional	
anatomy	it	functions	as	a	one-way	valve.	This	allows	deoxygenated	blood	to	be	pumped,	
unobstructed,	from	the	right	ventricular	chamber	into	the	pulmonary	trunk	during	systole	
(antegrade	flow)	and	stops	backflow	from	the	pulmonary	trunk	into	the	right	ventricular	
chamber	during	diastole	(regurgitation)	(Gross	&	Kugel,	1931).		
2.1.5.	Pulmonary	Arterial	Circulation	Impediment	and	Embryology	
	As	can	be	inferred	from	the	embryology	of	the	heart,	pulmonary	trunk	and	main	
pulmonary	arteries,	abnormalities	in	development	of	the	conus	cordis,	truncus	arteriosus,	
6th	arch	structures,	aorticopulmonary	septum	and	the	pulmonary	valve	can	result	in	a	
spectrum	of	native	pulmonary	arterial	and	valve	abnormalities,	including	atresia	and	
various	degrees	of	stenosis.		The	net	result	of	these	abnormalities,	regardless	of	which	
level	they	occur	at,	is	impaired	peripheral	pulmonary	arterial	circulation	and	increasing	
severity	of	these	impediments	will	promote	the	formation	of	SPC/s.	No	publication	on	
predictable	SPC/s	morphology	correlating	to	specific	sites	and	degrees	of	PA/PS	was	
identified	in	the	literature.		
The	ductus	arteriosus,	characterised	as	an	aortic	arch	to	pulmonary	trunk	(PT)	
communication,	functions	as	a	right	to	left	shunt	antenatally,	allowing	circulating	blood	to	
bypass	the	foetuses	lungs.	If	this	connection	remains	open	antenatally	it	is	termed	a	
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patent	ductus	arteriosus	(PDA)	and	flow	reversal	occurs	resulting	in	left	to	right	shunting,	
thus	a	PDA	may	be	considered	to	be	a	form	of	SPC/s.	
2.2.	Congenital	Anomalies	featuring	Pulmonary	Atresia	or	Stenosis	
Close	to	thirty	percent	of	major	congenital	anomalies	are	cardiovascular	(van	der	Linde	et	
al.,	2011).	Mitchell,	Korones	&	Berendes	(1971)	defined	congenital	heart	disease	(CHD)	as	
“a	gross	structural	abnormality	of	the	heart	or	intrathoracic	great	vessels	that	is	actually	
or	potentially	of	functional	significance”.	Determining	the	incidence	of	congenital	heart	
disease	and	its	subtypes	has	many	confounding	factors	extensively	elaborated	on	by	
Hoffman	&	Kaplan	(2002)	but	their	meta-analysis	paper	undertakes	to	“estimate	its	true	
value	and	provide	data	about	the	incidence	of	specific	major	forms	of	CHD”.		The	more	
frequently	encountered	congenital	heart	diseases	featuring	pulmonary	atresia	or	stenosis	
in	accordance	with	Hoffman	&	Kaplan	(2002)	are	briefly	described	below.			
2.2.1	Pulmonary	Valve	Atresia	
The	incidence	of	pulmonary	valve	atresia	is	estimated	to	be	123	per	million	live	births	
globally	(Hoffman	&	Kaplan,	2002).	Most	commonly	this	arises	as	a	congenital	
malformation	where	the	pulmonary	valve	does	not	develop	appropriately.	
Characteristically	there	is	a	dense	tissue	membrane	in	its	place.	Thus	in	pulmonary	valve	
atresia	there	is	no	luminal	continuity	between	the	right	ventricular	chamber	and	the	
pulmonary	trunk	(Tchervenkov	&	Roy,	2000).	Postnatally	acquired	causes	of	pulmonary	
stenosis	such	as	rheumatic	heart	disease	and	infective	endocarditis	are	extremely	rare	
(Hoffman	&	Kaplan,	2002).	As	they	are	acquired	after	the	cessation	of	cardiogenesis,	it	
corresponds	that	they	do	not	have	associated	systemic	to	pulmonary	collateral	arteries.		
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2.2.2	Tetralogy	of	Fallot		
The	incidence	of	Tetralogy	of	Fallot	(TOF)	is	estimated	to	be	421	per	million	live	births	by	
(Hoffman	&	Kaplan,	2002).	As	the	word	tetralogy	infers,	TOF	is	the	combination	of	four	
abnormalities,	namely	pulmonary	outflow	tract	stenosis,	right	ventricular	hypertrophy	
(RVH),	ventricular	septal	defect	(VSD)	and	an	overriding	aorta.	However,	it	is	important	to	
understand	that	these	abnormalities	are	the	result	of	a	single	conus	arteriosus	
developmental	anomaly,	where	there	is	deficient	expansile	growth	of	the	subvalvular	
infundibulum.	The	term	“monology	of	Stensen”	was	coined	by	Stella	van	Praagh	in	1970	
with	deference	to	Neils	Stensen,	who	first	described	the	anomaly	that	later	became	
known	as	TOF	(van	Praagh,	2009);	(Banderker,	Pretorius,	&	De	Decker,	2015);	(Walker,	
Rosado-de-Christenson,	Martinez-Jimenez,	Kunin,	&	Wible,	2015);	(Sheikh,	Kazmi,	&	Syed,	
2014);	(Frank	et	al.,	2010).	
2.2.3	Truncus	Arteriosus	
The	incidence	of	truncus	arteriosus	is	estimated	to	be	107	per	million	live	births	(Hoffman	
&	Kaplan,	2002)	and	is	characterised	by	the	presence	of	a	single	great	artery	originating	
from	the	cardiac	base	with	a	concomitant	ventricular	septal	defect.	This	single	great	
artery	has	only	one	corresponding	semilunar	valve	and	the	coronary,	pulmonary	and	
systemic	arteries	arise	from	it	(Collett	&	Edwards,	1949);	(Crupi,	Macartney,	&	Anderson,	
1977).	Pulmonary	arterial	anomalies	including	complete	absence	and	stenosis	are	
commonly	associated	with	truncus	arteriosus	(Butto,	Lucas,	&	Edwards,	1986).	
2.2.4	DiGeorge	Syndrome	
DiGeorge	syndrome	is	a	subcategory	of	22q11.2	deletion	syndrome,	with	the	presence	of	
immune	compromise	being	the	primary	differentiator	from	the	other	subcategories.	
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Cardiovascular,	facial,	intellectual,	immunological	and	endocrine	abnormalities	are	
recognised	features	of	DiGeorge	syndrome.	Of	the	cardiovascular	abnormalities,	
conotruncal	anomalies	including	TOF	and	truncus	arteriosus	are	the	most	common	(Chen	
et	al.,	2016);	(De	Decker	et	al.,	2016).	
2.2.5	Congenital	Rubella	
Rubella	is	a	well-known	teratogenic	virus.	Infection	during	the	first	trimester	may	give	rise	
to	a	wide	variety	of	congenital	abnormalities	with	the	frequent	inclusion	of	pulmonary	
arterial	stenosis	(Yazigi	et	al.,	2017).		
2.3.	Pulmonary	Atresia	Classification	and	Basic	Surgical	Principles	
According	to	Leonard,	Derrick,	O’Sullivan	&	Wren	(2000)	pulmonary	atresia	may	broadly	
be	divided	into	pulmonary	atresia	with	intact	ventricular	septum	(PA-IVS);	pulmonary	
atresia	with	ventricular	septal	defect	(PA-VSD);	and	pulmonary	atresia	accompanied	by	
more	complex	anomalies.	PA-IVS	is	described	as	having	conventional	atria	and	
atrioventricular	concordance	and	a	complete	interventricular	septum;	PA-VSD	is	
described	as	having	normal	atria	and	atrioventricular	concordance	but	an	incomplete	
interventricular	septum;	and	pulmonary	atresia	accompanied	by	more	complicated	
deformities	includes	cases	that	do	not	comply	with	the	first	two	categories	such	as	those	
with	tricuspid	valve	atresia	or	a	double	outlet	right	ventricle.		
	
The	management	of	pulmonary	atresia	with	ventricular	septal	defect	is	principally	
influenced	by	the	architecture	of	the	pulmonary	circulation	and	to	a	lesser	extent	the	
intracardiac	anatomy	(Tchervenkov	&	Roy,	2000);	(Hayabuchi,	Mori,	Kitagawa,	Inoue,	&	
Kagami,	2007);	(Fang	et	al.,	2011).	
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SPC/s,	as	the	nomenclature	implies,	arise	from	the	systemic	circulation	and	supply	the	
lungs.	SPC/s	include	MAPCA/s,	which	classically	stem	from	the	descending	thoracic	aorta	
and	more	rarely	from	the	aortic	arch	or	abdominal	aorta.	Infrequently	SPC/s	derive	their	
origin	from	the	subclavian,	carotid	or	coronary	arteries.	Pulmonary	blood	flow,	especially	
in	cases	of	PA-VSD,	may	also	be	derived	from	an	augmented	system	of	bronchial	arteries.	
Even	paramediastinal	and	intercostal	arteries	are	known	to	occasionally	contribute	to	the	
pulmonary	circulation	(Maeda	et	al.,	2006).	Consequently,	pulmonary	blood	supply	in	
cases	of	pulmonary	atresia	may	be	exceedingly	complex	and	is	further	complicated	by	the	
natural	progression	of	the	disorder,	as	these	vessels	routinely	develop	pulmonary	
hypertension	or	stenose,	resulting	in	pulmonary	hypoperfusion	and	incapacitating	
hypoxaemia	(Brown,	Eyskens,	Mertens,	Dumoulin,	&	Gewillig,	1998).	There	is	a	theory	
that	SPC/s	are	bronchial	arteries	that	would	normally	regress	but	have	instead	dilated	to	
supplement	or	provide	pulmonary	blood	flow.	This	is	supported	by	the	morphological	
similarities	between	SPC/s	and	bronchial	arteries	and	the	lack	of	normal	native	bronchial	
arteries	in	patients	with	SPC/s	(Norgaard	et	al.,	2006);	(Walker	et	al.,	2015).	It	is	
postulated	that	the	cellular	programming	for	primitive	bronchial	arteries	to	involute	is	
impaired	by	the	altered	pulmonary	haemodynamic	requirement	and	hence	these	vessels	
persist	as	stenosed	vessels	of	pulmonary	supply.	Palliative	endovascular	intervention	in	
the	form	of	balloon	dilation	or	stenting	is	known	to	result	in	acceptable	clinical	
improvement	in	pulmonary	blood	flow	in	cases	of	stenosis	(Brown	et	al.,	1998).	
	
Tchervenkov	&	Roy	(2000)	proposed	a	type	A,	B	and	C	classification	system	premised	on	
pulmonary	circulation	morphology.		Ostensibly	the	term	MAPCA/s	in	this	and	the	
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following	classification	systems	is	used	to	incorporate	all	SPC/s	and	will	not	be	altered	in	
the	interest	of	accurate	reference.	
In	Type	A,	pulmonary	blood	flow	is	solely	via	native	pulmonary	arteries	and	MAPCA/s	are	
not	present.		
In	Type	B,	a	combination	of	native	pulmonary	arteries	and	MAPCA/s	exist.	
In	Type	C,	pulmonary	blood	flow	is	solely	via	MAPCA/s	and	native	pulmonary	arteries	are	
not	present.	
	
A	comparable	classification	system	had	already	been	published	by	Barbero-Marcial	&	
Jatene	(1990)	also	categorizing	pulmonary	circulation	in	the	presence	of	pulmonary	
atresia	with	ventricular	septal	defect	into	types	A,	B	and	C,	and	Mace	et	al.	(1996)	
reiterated	and	further	elaborated	on	the	Barbero-Marcial	&	Jatene	(1990)	classification.	
In	Type	A,	the	central	pulmonary	arteries	supply	every	bronchopulmonary	segment	and	
the	primary	surgical	concern	is	whether	the	existing	pulmonary	arteries	offer	the	
potential	for	definitive	correction.	Type	A	is	further	subdivided	into	A1	where	the	
pulmonary	arteries	range	from	normal	to	hypoplastic	and	A2	where	the	pulmonary	
arteries	are	stenotic	or	non-confluent.	
In	Type	B	there	is	a	combination	of	branch	central	pulmonary	arteries	and	MAPCA/s,	
blood	flow	to	each	bronchopulmonary	segment	being	provided	by	one	or	the	other.	
When	this	configuration	occurs,	the	primary	surgical	undertaking	is	to	join	(“unifocalise”)	
the	MAPCA/s	to	the	existing	pulmonary	arteries,	thus	amalgamating	the	entire	pulmonary	
circulation	and	promoting	conventional	growth	with	a	view	to	subsequent	definitive	
repair.	
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In	Type	C,	only	MAPCA/s	provide	blood	flow	to	all	of	the	bronchopulmonary	segments,	as	
the	central	pulmonary	arteries	are	completely	atretic.		In	this	instance,	the	primary	
surgical	undertaking	is	to	join	the	MAPCA/s	to	existing	lobar	arteries	and	fashion	an	
interposed	connecting	pulmonary	artery	and	an	accompanying	systemic	to	pulmonary	
artery	shunt,	also	with	a	view	to	subsequent	definitive	repair.		
	
Allowing	for	the	clear	similarities	between	the	proposed	classifications,	the	Tchervenkov	
&	Roy	(2000)	classification	claims	to	be	a	simpler,	more	encompassing	and	applicable	to	
both	recent	management	trends,	including	“primary	repair	in	type	A	and	the	single	stage	
unifocalization	±	repair	in	types	B	and	C”,	as	well	as	customary	multistage	management	
techniques.	
	
Maeda	et	al.	(2006)	emphasizes	that	it	is	critical	to	describe	all	vasculature	comprising	the	
pulmonary	circulation	prior	to	operative	intervention.	Any	available	collateral	arteries,	
including	MAPCA/s,	bronchial	and	non-bronchial	collateral	systemic	vessels,	may	be	
utilized	for	surgical	reconstruction	(Kouchoukos	&	Kirklin,	2003).	Furthermore,	any	missed	
MAPCA/s	that	should	be	tied	off	may	result	in	a	detrimental	persistent	“left	to	right”	
shunt.		
	
Quantitative	indices	including	the	McGoon	ratio,	Pulmonary	Arterial	Index	(PAI)	and	Total	
Neopulmonary	Arterial	Index	(TNPAI)	are	frequently	employed	to	determine	the	necessity	
for	surgical	intervention.		
The	McGoon	ratio	is	the	summation	of	the	diameters	of	the	left	and	right	main	
pulmonary	arteries	just	prior	to	their	first	order	division	divided	by	the	diameter	of	the	
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aorta	at	the	level	of	the	diaphragm;	the	PAI	is	the	summation	of	the	cross-sectional	areas	
of	the	left	and	right	main	pulmonary	arteries	just	prior	to	their	first	order	division	divided	
by	the	body	surface	area;	and	the	TNPAI	is	the	summation	of	the	cross-sectional	areas	of	
the	left	and	right	main	pulmonary	arteries	just	prior	to	their	first	order	division	as	well	as	
the	cross-sectional	area	of	SPC/s	divided	by	the	body	surface	area	(Yin	et	al.,	2011).		
These	indices	were	proposed	based	on	vessel	parameters	determined	by	invasive	
angiography	(IA)	and	influence	the	necessity,	type	and	timing	of	repair.	However,	MDCTA	
has	effectively	superseded	IA	to	determine	these	indices.	
	
While	variations	in	utilitarian	classification	of	pulmonary	atresia	and	pulmonary	blood	
supply	persist,	the	uniform	thread	is	that	acute,	on-going	and	definitive	surgical	
management	is	dependent	on	accurately	elucidating	the	prevailing	pulmonary	vascular	
anatomy.		
	
2.4.	Pulmonary	Circulation	Imaging	Techniques		
Echocardiography,	magnetic	resonance	imaging	(MRI),	multidetector	computed	
tomography	angiography	(MDCTA)	and	invasive	angiography	(IA)	will	be	discussed	as	
modalities	employed	in	evaluation	of	the	pulmonary	circulation.		It	is	important	to	
consider	the	limited	availability	of	some	or	all	of	these	resources,	both	in	terms	of	
facilities	and	expertise.	
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2.4.1.	Echocardiography	
It	has	been	demonstrated	in	infants	that	the	morphology	of	central	pulmonary	arteries	
can	be	reliably	determined	using	echocardiography	(Smyllie,	Sutherland,	&	Keeton,	1989);	
(Acherman,	Smallhorn,	&	Freedom,	1996);	(Mackie,	Gauvreau,	Perry,	del	Nido,	&	Geva,	
2003).	Operator	dependence	does,	however,	play	a	major	role	in	this	form	of	imaging	and	
while	echocardiography	may	hint	at	the	presence	of	SPC/s,	acoustic	window	constraints	
often	preclude	comprehensive	evaluation	of	their	course	and	precise	morphology.	The	
difficulties	of	echocardiography	in	older/bigger	children	are	also	well	established	
(Rajeshkannan	et	al.,	2010).	Despite	these	limitations,	echocardiography	remains	the	
principal	modality	in	the	initial	evaluation	of	CHD	because	it	is	commonly	available,	
portable,	cost-effective	and	has	no	radiation	burden.		
	
The	use	of	additional	or	alternative	imaging	modalities	is	thought	necessary	in	only	a	
minority	of	cases	where	the	information	that	echocardiography	elicits	is	regarded	as	
incomplete	(Banderker	et	al.,	2015).		
	
2.4.2.	Cardiovascular	Magnetic	Resonance	Imaging		
Advances	in	magnetic	resonance	imaging	(MRI)	such	as	ECG-gated	cardiovascular	MRI	
(CMR)	and	contrast	enhanced	MRI	angiography	(MRA)	provide	exceptionally	good	quality	
images	with	comprehensive	morphological	and	functional	cardiac	and	extra-cardiac	
information	without	the	dangers	of	ionizing	radiation	and	iodinated	contrast	agents	
(Prasad	et	al.,	2004);	(Geva,	Greil,	Marshall,	Landzberg,	&	Powell,	2002);	(Boechat	et	al.,	
2005);	(Banderker	et	al.,	2015).	Limited	availability	especially	in	the	South	Africa	public	
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sector,	expense,	non-portability,	lengthy	sedation	or	anaesthesia,	MRI	incompatibility	of	
anaesthetic	and	ICU	equipment	and	certain	metallic	implants,	suboptimal	airway	and	lung	
depiction,	gadolinium	induced	risk	for	nephrogenic	systemic	sclerosis	(NSF)	and	lengthy	
post	processing	demands,	present	major	deterrents	to	the	use	of	these	imaging	
techniques	(Rajeshkannan	et	al.,	2010);	(Banderker	et	al.,	2015).	 
	
2.4.3.	Multidetector	Computed	Tomography	Angiography	vs.	Invasive	
Angiography	
Invasive	angiography,	traditionally	recognised	as	the	gold	standard	for	the	preoperative	
assessment	of	pulmonary	circulation	morphology	(Maeda	et	al.,	2006);	(Hayabuchi	et	al.,	
2007),	has,	over	the	past	two	and	a	half	decades,	largely	been	superseded	by	the	
increasing	value	of	computed	tomography	angiography	as	a	suitable	means	of	mapping	
vascular	anatomy.			
	
Rubin,	Armerding,	Dake	&	Napel	(2000)	reported	that	CTA	had	become	a	significant	
method	for	assessing	vascular	morphology,	having	even	better	diagnostic	capability	than	
IA	in	certain	instances,	as	well	as	being	more	cost	effective.		This	opinion	was	reiterated	
by	Lawler	&	Fishman	(2001)	Siegel	(2003)	and	Remy-Jardin	(2004).		
	
Griel	et	al.	(2006)	found	that	there	was	a	high	inter-observer	correlation	when	specifically	
comparing	MDCTA	to	traditional	angiography	for	the	visualization	of	MAPCA/s	and	their	
morphology,	concluding	that	MDCTA	can	be	employed	as	an	accurate	“alternative	to	
diagnostic	cardiac	catheterization	and	selective	angiography.”	
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Hayabuchi	et	al.	(2007)	concluded	similarly	in	a	study	specifically	evaluating	the	size	and	
morphology	of	the	pulmonary	arteries,	and	Hayabuchi	et	al.	(2010)	also	demonstrated	
strong	correlation	between	MDCTA	and	IA.	
	
The	manipulation	of	volumetric	data	sets	obtained	by	MDCTA	into	multiplanar	and	three-
dimensional	reconstructions	allows	for	vascular	anatomy	to	be	evaluated	from	any	
direction	and	facilitates	quantification	not	achievable	by	projection	methods	like	IA	
(Rubin,	Dake,	Napel,	McDonnell,	&	Jeffrey,	1993);	(Rubin,	Paik,	Johnston,	&	Napel,	1998).	
Lawler	and	Fishman	(2001)	established	along	similar	lines	that	MDCTA	could	differentiate	
vessels	overlying	one	another	(especially	the	aorta),	which	is	difficult	on	projection	
imaging.	Other	advantages	of	MDCTA	over	IA	include	being	less	invasive	(IA	may	be	
entirely	precluded	due	to	a	patient’s	critically	ill	condition)	and	more	cost	effective	
(Rubin,	Armerding,	et	al.,	2000),	as	well	as	having	the	ability	to	demonstrate	extracardiac	
and	nonvascular	thoracic	pathology	(Katz,	Jorgensen,	&	Rubin,	1999).		Maeda	et	al.	(2006)	
added	that	information	on	the	spatial	relations	of	vessels	supplying	non-vascular	
pathology	would	be	detailed	by	MDCTA.		Maeda	et	al.	(2006)	also	purported	that	MDCTA	
detailed	all	vasculature	within	the	obtainable	spatial	resolution	and	scanned	volume	
within	a	single	acquisition,	whereas	multiple	selective	catheterizations	are	necessary	in	IA	
to	describe	different	vessels.	With	regard	to	comparative	radiation	exposure,	
Chandrashekhar,	Sodhi,	Saxena,	Rohit	&	Khandelwal	(2012)	reported	doses	when	using	
MDCTA	that	were	considerably	less	than	doses	described	in	cardiac	catheterization	
angiography.		
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While	both	IA	and	MDCTA	allow	for	functional	assessment	of	flow,	IA	also	allows	for	
measurement	of	intravascular	pressures,	important	in	the	presence	of	SPC/s	as	they	can	
cause	pulmonary	hypertension.		Furthermore,	MDCTA	functional	assessment	comes	at	
the	expense	of	the	dose	penalty	imposed	by	ECG	gating.		
	
A	further	advantage	of	IA	is	that	direct	conversion	to	endovascular	intervention	is	
possible	if	needed	(Maeda	et	al.,	2006);	(Hayabuchi	et	al.,	2007).	Remy-Jardin	et	al.	(2004)	
and	Hayabuchi	et	al.	(2007)	do,	however,	demonstrate	that	MDCTA	studies	done	prior	to	
endovascular	procedures,	aid	in	the	ease	of	direct	selective	catheterization	as	well	as	
shortening	theatre	time	and	iatrogenic	complications.		
2.4.4.	Evolution	of	Multi	Detector	Computed	Tomography	and	the	Relevance	of	
Improved	Capabilities	
Rubin	et	al.	(1999)	demonstrated	that	MDCT	scanners	are	more	efficient	than	single	
detector	computed	tomography	(SDCT)	scanners	in	terms	of	acquisition	speed	and	
longitudinal	spatial	resolution	when	performing	computed	tomography	angiography	
(CTA).		
	
Rubin	et	al.	(2000)	(Rubin,	Shiau,	et	al.,	2000)	specifically	compared	4-MDCT	to	SDCT	and	
concluded	that	4-MDCT	presented	considerable	advantages	not	only	in	terms	of	
acquisition	speed	and	longitudinal	spatial	resolution	but	also	in	markedly	reducing	the	
volume	of	contrast	material	necessary	for	adequate	imaging	quality.		
	
Maeda	et	al.	(2006)	compared	the	16-MDCT	to	4-MDCT	with	particular	interest	in	
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assessment	of	bronchial	systemic	collateral	arteries.	The	bronchial	systemic	collateral	
arteries	were	thought	to	be	inadequately	depicted	by	4-MDCT	as	their	average	diameter	
is	1,5	mm	(Pump,	1972),	rendering	2	mm	collimation	insufficient.	16-MDCT	augmented	
the	previously	discussed	benefits	of	MDCT,	allowing	a	greater	area	to	be	scanned	with	
narrower	1	mm	collimation	over	a	briefer	period	of	time.		It	was	found	that	MAPCA/s,	
bronchial	and	non-bronchial	systemic	collateral	arteries	were	consistently	and	accurately	
depicted	in	terms	of	their	‘numbers	and	sites	of	origin,	their	varying	diameters,	their	
courses,	and	the	areas	of	the	lungs	they	supply’	(Maeda	et	al.,	2006).	
	
Greil	et	al.	(2006),	Hayabuchi	et	al.	(2007)	and	Hyabuchi	et	al.	(2010)	using	16-MDCT	in	
their	studies,	both	demonstrated	strong	correlation	between	MDCT	and	IA	findings.	
	
Leber	et	al.	(2006)	stated	that	the	advent	of	64-MDCT	would	inevitably	improve	imaging	
precision	and	that	MDCTA	would	further	supersede	IA	as	the	vascular	imaging	method	of	
choice.	
	
A	study	by	Rajeshkannan	et	al.	(2010)	using	64-MDCT	concluded	that	MDCTA	and	its	data	
post	processing	capabilities	such	as	multiplanar	and	3D	reconstruction	are	critical	to	the	
diagnosis	and	management	planning	of	PA-VSD,	increasingly	replacing	IA.		
	
Yin	et	al.	(2011)	demonstrated	that	dual	source	computed	tomography		(DSCT)	was	better	
at	identifying	and	describing	MAPCAs	and	native	pulmonary	arteries	than	IA.	This	was	
thought	to	be	largely	attributable	to	the	ability	of	multiplanar	and	3D	reconstruction	to	
eliminate	the	superimposition	of	vessels	experienced	with	IA.	It	was	also	formally	
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reported	by	Yin	et	al.	(2011)	that	DSCT	quantitative	measurements	strongly	correlated	
with	IA,	allowing	for	accurate	calculation	of	the	McGoon	ratio,	PAI	and	TNPAI,	which,	as	
discussed,	play	a	critical	role	in	surgical	decision-making.	
2.5.	Our	Study	in	Context	
	
In	our	study	we	used	64-MDCTA	to	evaluate	the	cardiovascular	system	with	specific	
reference	to	PA	and	SPC/s.		
Accurate	imaging	is	critical	to	the	management	of	pulmonary	atresia/stenosis	and	MDCTA	
with	16	rows	and	above	is	comparable	to	the	conventionally	accepted	gold	standard	of	IA,	
both	in	terms	of	demonstrating	the	pulmonary	arterial	morphology	and	quantitative	
functional	analyses.	Furthermore,	MDCTA	is	emerging	as	the	imaging	modality	of	choice	
in	when	employed	in	isolation	or	in	combination	with	other	modalities	due	to	its	many	
additional	advantages,	such	as	having	less	exposure	to	ionizing	radiation,	being	less	
invasive,	less	time	consuming,	more	cost	effective	and	depicting	potentially	influential	
nonvascular	thoracic	pathology.	In	addition,	MDCTA	has	the	major	benefits	of	multiplanar	
reconstruction	and	three-dimensional	reconstruction	that	further	aids	in	ease	of	
information	conveyance	to	the	involved	clinicians	and	surgeons.			
	
Several	studies	discuss	SPC/s	in	patients	with	PA/PS	but	little	emphasis	is	placed	on	their	
relative	frequencies	and	standardised	nomenclature.	Knowing	the	relative	frequencies	of	
specific	SPC/s	will	help	to	direct	the	investigating	radiologists,	cardiologists	and	
cardiothoracic	surgeons	in	a	systematic	search	for	these	vessels.	
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Identifying	the	various	sites	of	origin	other	than	from	the	aorta	will	support	using	the	
term	“systemic	to	pulmonary	collateral	artery/s”	(SPC/s)	rather	than	“major	
aortopulmonary	collateral	artery”	(MAPCA/s)	as	the	broader	term,	with	the	term	
MAPCA/s	being	reserved	for	use	as	a	specific	subdivision	of	SPC/s.		Knowing	possible	sites	
of	non-aortic	origin	SPC/s	and	their	frequency	may	give	insight	into	further	suitable	
subdivisions	and	help	to	develop	an	accurate,	informative	and	standardised	
nomenclature	system.	
	
3.	Aims		
This	study	aims	to	guide	radiologists,	cardiologists	and	cardiothoracic	surgeons	in	their	
search	for	systemic	to	pulmonary	collateral	arteries	and	to	recommend	an	accurate,	
informative	and	standardised	nomenclature	system	for	systemic	to	pulmonary	collateral	
arteries	by	establishing	the	relative	frequencies	of	origin	of	systemic	to	pulmonary	
collateral	arteries	in	patients	with	pulmonary	atresia/stenosis	using	multidetector	
computed	tomography	angiography.	
	
4.	Objectives	
1.	To	create	a	sample	group	of	patients	from	the	cohort	of	thoracic	cardiovascular	cases	
scanned	using	multidetector	computed	tomography	angiography	at	Red	Cross	War	
Memorial	Children’s	Hospital	between	November	2013	and	November	2017	that	were	
found	to	have	pulmonary	atresia/stenosis	with	a	patent	ductus	arteriosus	and/or	
systemic	to	pulmonary	collateral	arteries		
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2.	To	identify	the	various	origins	of	systemic	to	pulmonary	collateral	arteries	within	the	
sample	group,	using	multidetector	computed	tomography	angiography.	
3.	To	evaluate	the	relative	frequencies	of	the	identified	systemic	to	pulmonary	collateral	
artery	origins	within	the	sample	group.	
	
5.	Study	Procedure	
5.1.	Research	Paradigm	
In	conjunction	with	the	University	of	Cape	Town	biostatistician,	William	Msemburi,	the	
research	paradigm	was	determined	to	be	a	retrospective	descriptive	study.		
	
5.2.	Sample	
The	sample	group	for	this	study	was	selected	from	patients	who	had	undergone	thoracic	
cardiovascular	MDCTA	at	Red	Cross	War	Memorial	Children’s	Hospital,	Cape	Town,	South	
Africa	(RCWMCH)	during	the	period	November	2013	to	November	2017.	RCWMCH	is	the	
largest	dedicated	paediatric	hospital	in	Southern	Africa	with	300	beds	and	
accommodating	an	estimated	260	000	patient	visits	annually.	It	is	a	government	run	
public	service	hospital	affiliated	to	both	the	University	of	Cape	Town	and	the	University	of	
Stellenbosch	providing	a	near	full	spectrum	of	paediatric	health	care	services	and	training	
at	secondary,	tertiary	and	quaternary	levels.	RCWMCH	is	a	referral	centre	not	only	for	
South	Africa	but	also	for	the	entire	sub-continent.		
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5.2.1.	Inclusion	criteria	
All	patients	where	the	thoracic	cardiovascular	MDCTAs	demonstrated	PA/PS	with	a	PDA	
and/or	SPC/s	were	included	in	the	study.	Whilst	the	admissions	age	range	of	RCWMH	is	
birth	to	13	years,	the	age	range	included	patients	outside	of	the	institutional	age	limit	by	
special	managerial	consent.		
	
5.2.2.	Exclusion	criteria	
All	patients	where	the	SPC/s	origin	could	not	be	determined	on	both	first	and	second	
readings	of	the	thoracic	cardiovascular	MDCTAs	were	excluded	from	the	study.	
5.3.	Materials	and	Methods	
Despite	the	retrospective	nature	of	this	study,	the	MDCTA	acquisition	technique	was	
standardised	over	the	period	of	investigation.	
5.3.1.	Hardware	and	Software	
5.3.1.1.	Multi-detector	Computed	Tomography	Scanner	
Philips	Brilliance	CT	64	slice:	NCTB422;	software	version	2.4.5	–	configurations	as	listed	in	
Appendix	1.	
5.3.1.2.	Multi-detector	Computed	Tomography	Scanner	Workspace	
	Philips	Workspace:	NCTA440;	software	version	4.0.0	–	configurations	as	listed	in	
Appendix	2.	
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5.3.1.3.	Injection	System	for	Computed	Tomography	Investigations	
Bayer	Medran	Stellant	CT	Injection	System:	SCT	212	–	system	and	mechanical	
specifications	as	listed	in	Appendix	3.	
5.3.1.4.	Reporting	Station	
Hardware:	Two	diagnostic	monitors;	tower;	navigation	monitor.	
Software:	Xiris	booking	platform;	ISITE	viewing	platform;	XRE2	reporting	platform.	
System	and	mechanical	specifications	as	listed	in	Appendix	4.	
	
5.3.2.	Standard	Multi-detector	Computed	Tomography	Angiography	Acquisition	
Protocols	at	Red	Cross	War	Memorial	Children’s	Hospital	
5.3.2.1.	Non-ECG-Synchronised	Cardiac	and	Chest	MDCTA	RCWMCH	Protocol		
Personnel	appropriately	skilled	in	paediatric	sedation	or	anaesthesia	and	in	the	
management	of	cardiac	emergencies	were	present	during	the	time	of	imaging	acquisition.		
Iodine	allergy	was	excluded.	A	large	bore	intra-venous	(IV)	cannula	was	sited	in	the	
antecubital	fossa	contralateral	to	the	aortic	arch.	A	20	-22	gauge	IV	cannula	was	deemed	
to	be	acceptable	for	the	procedure	with	a	preference	for	a	20	gauge	IV	cannula	in	
patients	older	than	three	years	or	where	ECG-synchronised	MDCTA	was	performed.	Non-
ionic	iodinated	contrast	with	a	volume	of	2ml/kg	bodyweight	was	administered	at	a	rate	
of	2ml/second	using	a	CT	specific	automated	injecting	system.	A	bolus	tracking	technique	
was	used	with	the	scan	trigger	set	at	150	Hounsfield	unit	(HU)	using	a	region	of	interest	
(ROI)	in	the	descending	thoracic	aorta	at	the	level	of	the	carina.	For	the	non-ECG-
synchronised	cardiac	protocol	a	10-15	ml	chasing	bolus	of	50%	dilution	contrast-saline	
solution	was	administered	(Banderker	et	al.,	2015).	
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5.3.2.2.	Utility	of	Electrocardiogram-Synchronised	Cardiac	Multidetector	
Computed	Tomography	Red	Cross	War	Memorial	Hospital	Protocol	
As	a	rule	studies	were	performed	without	electrocardiogram	(ECG)	gating	due	to	the	
requirement	of	pharmacological	heart	rate	manipulation	in	often	critically	ill	patients,	the	
dose	penalty	incurred	and	technical	difficulties	experienced	when	using	ECG-synchronised	
MDCTA.	Only	retrospective	ECG-gating	is	available	at	RCWMCH	whilst	the	more	expensive	
but	radiation-sparing	prospective	gating	software	is	as	yet	not	available.	ECG-gated	
MDCTA	is	only	utilized	in	specific	indications	where	coronary	artery	anomalies	are	
suspected,	based	on	echocardiographic	findings.	For	example,	a	large	conus	branch	of	the	
right	coronary	artery	overlying	the	right	ventricular	outflow	tract	is	at	risk	of	being	
transected	during	augmentation	surgery	of	the	outflow	tract	and	must	be	confirmed	prior	
to	surgical	intervention.		
	
5.3.3.	Case	Creation	
Patients	requiring	cardiac	MDCTA	were	scheduled	on	the	RCWMCH	booking	platform	
(XIRIS).	
A	64-MDCT	scanner	(Philips	Brilliance)	was	used	in	accordance	with	either	the	standard	
RCWMCH	cardiac	MDCTA	protocol	or	using	the	less	frequently	employed	retrospective	
ECG-synchronised	MDCTA	protocol.			
Patient	details	and	history,	was	transferred	from	the	booking	platform	to	the	reporting	
platform	(XRE2)	in	each	case.	The	images	were	linked	to	each	case	and	transferred	to	the	
viewing	platform	(Philips	ISITE).	
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5.3.4	Interpretation	and	Reporting	
The	images	were	interpreted	by	a	radiology	registrar	and	a	specialist	radiologist	on	the	
viewing	platform	(Philips	ISITE)	using	the	source	images,	maximum	intensity	projection	
(MIP),	slice	thickness	manipulation,	multiplanar	reconstruction	and	three-dimensional	
reconstruction.	A	provisional	report	was	then	generated	on	the	reporting	platform	
(XRE2).	This	was	regarded	as	the	first	reading.	A	further	reading	prior	to	the	issuing	of	a	
final	report	was	performed	with	the	involved	cardiologists	and	cardiothoracic	surgeons	in	
attendance.		
5.4.	Data	Collection,	Analysis	and	Statistics	
Detailed	consultation	with	the	University	of	Cape	Town	biostatistician,	William	Msemburi,	
determined	the	research	paradigm	to	be	a	retrospective	descriptive	study.	The	statistical	
analysis	appropriate	to	the	objectives	of	this	study	will	be	proportions	and	percentages.		
	
An	Excel	spreadsheet	of	all	cardiac	CTA	cases	done	at	RCWMCH	from	November	2013	to	
November	2017	was	created	by	the	principle	investigator.	This	was	done	by	applying	the	
filters	for	data	selection	of		‘CTA,	cardiac	and	CTA’	to	the	RCWMCH	Picture,	Archiving	and	
Communication	system	(PACS)	database	for	the	time	period	November	2013	to	
November	2017.	These	cases	were	anonymised	by	allocating	a	randomized	number	code	
to	each.	A	second	reading	of	these	cases	was	done	by	a	radiology	registrar	and	a	specialist	
radiologist	and	correlated	with	the	findings	of	the	first	reading.		Where	there	was	
discordance	between	the	first	and	second	readings,	the	second	reading	was	regarded	as	
definitive	as	it	was	done	by	the	most	experienced	RCWMCH	paediatric	radiologist	in	
cardiovascular	imaging.		Additional	information,	the	presence	of	PA/PS,	the	presence	of	a	
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PDA	and/or	SPC/s	and	the	artery	of	origin	of	each	SPC/s	was	added	to	each	case	and	
recorded	on	the	Excel	spreadsheet	(Appendix	5).	
An	Excel	spreadsheet	was	created	for	the	totals	of	the	number	of	cases	requiring	cardiac	
MDCTA;	the	number	of	cases	with	and	without	PA/PS;	the	number	of	cases	determined	to	
have	PA/PS	with	and	without	collateral	supply,	the	number	of	cases	with	a	PDA	and/or	
SPC/s;	the	number	of	cases	with	a	PDA	only;	the	number	of	cases	with	SPC/s	only;	the	
number	of	cases	with	both	a	PDA	and	SPC/s;	the	number	of	cases	with	a	single	SPC/s,	and	
the	number	of	cases	with	multiple	SPC/s.		(Appendix	6).	
An	Excel	spreadsheet	was	created	of	the	numbers	of	certain	congenital	heart	diseases	
(CHD)	and	related	additional	information,	their	percentage	of	the	total	MDCTA/s	
performed;	their	percentage	of	the	total	cases	with	pulmonary	atresia/stenosis;	the	
number	of	that	CHD	with	collateral	supply	and	percentage	of	total	cases	with	collateral	
supply;	the	number	of	that	CHD	with	a	PDA,	percentage	of	total	cases	with	a	PDA	and	
percentage	of	that	CHD	with	collateral	supply;	the	number	of	that	CHD	with	SPC/s,	
percentage	of	total	cases	with	SPC/s	and	percentage	of	that	CHD	with	collateral	supply;	
the	number	of	that	CHD	with	a	PDA	and	SPC/s,	percentage	of	total	cases	with	a	PDA	and	
SPC/s	and	percentage	of	that	CHD	with	collateral	supply.	(Appendix	7).			
An	Excel	spreadsheet	was	created	of	the	named	arteries	of	SPC/s	origin,	the	total	number	
of	cases	with	SPC/s	arising	from	that	named	artery	of	origin;	the	total	number	of	SPC/s	
arising	from	that	named	artery	of	origin;	the	percentage	of	the	total	number	of	SPC/s;	
number	of	cases	with	multiple	SPC/s	originating	from	the	same	named	artery	of	origin;	
and	the	percentage	of	that	named	artery	of	origin	with	multiple	SPC/s.	(Appendix	8)	
Using	Excel,	these	spreadsheets	were	further	represented	as	tables	and/or	graphs	to	
facilitate	ease	of	understanding.	
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5.5.	Reliability	and	validity	
Steps	taken	to	establish	reliability	include	multidisciplinary,	multiple	observer	readings	
performed	on	separate	occasions	of	each	MDCTA	ensuring	interobserver	and	temporal	
agreement	on	the	origin	of	each	SPC/s.		
Validity	was	established	by	ensuring	that	each	vessel	determined	to	be	a	SPC/s	fulfilled	
specific	defining	criteria	-	SPC/s	must	originate	from	a	systemic	artery	and	supply	
pulmonary	tissue	with	the	exclusion	of	conventional	bronchial	arteries.	
	
6.	Departmental	Research	and	Ethics	
6.1.	Departmental	Research	Committee	Approval	
Approval	was	obtained	from	the	Department	of	Radiation	Medicine,	Faculty	of	Health	
Sciences,	University	of	Cape	Town	and	the	Department	of	Paediatrics	and	Child	Health,	
Faculty	of	Health	Sciences,	University	of	Cape	Town.		
6.2.	Ethics	Approval	
Ethics	approval	was	obtained	from	the	Human	Research	Ethics	Committee,	Faculty	of	
Health	Sciences,	University	of	Cape	Town,	HREC	REF:		855/2017.		
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6.3.	Consent	forms	
Consent	is	null	and	void	as	this	is	a	retrospective	observational	study	and	has	no	potential	
to	influence	the	management	and	outcomes	of	the	sample	group	involved.	The	patients’	
cases	were	also	randomised	and	anonomised.	
6.4.	Data	safety	
Data	was	stored	on	a	private	password	protected	laptop.	Access	was	restricted	to	the	
primary	investigator	and	involved	supervisors.	Furthermore	the	patients’	cases	were	
anonomised	by	allocating	a	randomised	number	code	to	each	case.	Access	to	the	key	was	
again	restricted	to	the	primary	investigator	and	involved	supervisors.
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7.	Results	
7.1.	Note	on	PDA	Subcategory	
Please	note	that	PDA,	while	included	in	the	dissertation	because	it	is	a	systemic	to	
pulmonary	arterial	connection,	is	given	it’s	own	subcategory	designation	differentiating	it	
from	other	SPC/s.	
	
7.2.	Tables,	Figures	and	Written	Results	
Table	1.	Cardiac	CTA	Inclusion	Cases	
Case	 Additional	
Information	
Pulmonary	
Atresia/Stenosis		
(Yes	or	No)	
Patent	Ductus	
Arteriosus	
(Yes	or	No)	
Systemic	to	Pulmonary	Collateral	
Artery		
(Yes	or	No)	
		 		 		 		 		
1	 	 No	 No	 No	
2	 TOF	 Yes	 No	 No	
3	 PA		 Yes	 No	 No	
4	 TOF	 Yes	 No	 No	
5	 TOF	 Yes	 No	 No	
6	 TOF	 Yes	 No	 No	
7	 	 No	 No	 No	
8	 TOF	 Yes	 No	 No	
9	 TOF	 Yes	 No	 No	
10	 PA	and	VSD	 Yes	 No	 Yes:	Single:	1	from	AArch	with	a	
branch	to	the	RMPA	and	a	branch	to	
the	RLL	
11	 TOF	 Yes	 No	 No	
12	 	 No	 No	 No	
13	 PA	and	AVSD	 Yes	 No	 No	
14	 Interrupted	Aortic	
Arch	
No	 No	 No	
15	 Tricuspid	atresia	 Yes	 No	 No	
16	 	 No	 No	 No	
17	 Di	George	 Yes	 Yes	to	LMPA	 Yes:	Multiple:	1	from	LSCA	to	RML-
PA;	1	from	RSCA	to	RUL-PA;	1	from	
AArch	to	LMPA	
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18	 TOF	 Yes	 Yes	 No	
19	 Situs	Inversus	with	
DORV	
No	 No	 No	
20	 	 No	 No	 No	
21	 VACTERL;	agenesis	of	
the	R	lung,	RPA,	RPVs	
and	R	MB	
Yes	 No	 No	
22	 PA	and	VSD	 Yes	 No	 No	
23	 	 No	 No	 No	
24	 TOF	 Yes	 No	 No	
25	 TOF	 Yes	 No	 No	
26	 No	 No	 No	 No	
27	 PA	and	VSD	 Yes	 No	 No	
28	 TOF	 Yes	 No	 No	
29	 TOF	 Yes	 No	 No	
30	 Truncus	Arteriosus	 No	 No	 No	
31	 TOF	 Yes	 Yes	to	LMPA	 No	
32	 	 No	 No	 No	
33	 	 No	 No	 No	
34	 Aortic	Coarctation	 No	 No	 No	
35	 Dextrocardia	with	
Right	Isomerism	
Yes	 Yes	to	RMPA	
(Right	sided	
AArch)	
No	
36	 PA	and	VSD	 Yes	 No	 Yes:	Multiple:	3	from	DA	forming	a	
plexus	supplying	the	RLL	and	LLL	
37	 	 No	 No	 No	
38	 TOF	 Yes	 Yes	to	LMPA	 Yes:	Multiple:	1	from	Right	Vertebral	
Artery	to	RUL;	1	from	DA	to	
posterior	and	medial	basal	segments	
of	the	RLL	
39	 	 No	 No	 No	
40	 TOF	 Yes	 No	 Yes:	Multiple:	1	from	Arch	to	LMPA;	
1	from	DA	to	RMPA		
41	 TOF	 Yes	 No	 No	
42	 TOF	 Yes	 No	 No	
43	 	 No	 No	 No	
44	 TOF	 Yes	 No	 No	
45	 PA	and	VSD	 Yes	 No	 Yes:	Multiple:	1	from	LSCA	to	LMPA;	
1	from	DA	to	RUL;	1	DA	to	RML	
46	 Absent	Pulmonary	
Valve	Syndrome	
Yes	 No	 Yes:	Multiple:	1	from	DA	to	RUL;	1	
from	DA	to	RML	and	RLL	
47	 TOF	 Yes	 No	 No	
48	 TOF	 Yes	 No	 No	
49	 	 No	 No	 No	
50	 TOF	 Yes	 No	 No	
51	 	 No	 No	 No	
52	 Truncus	Arteriosus	 Yes	 No	 No	
40	
	
53	 Multiple	
Abnormalities	
Yes	 Yes	to	LMPA	 Yes:	Single:	1	from	
Infradiaphragmatic	to	Right	Lung		
54	 Situs	Inversus	Totalis	 No	 No	 No	
55	 Congenital	Rubella	 Yes	 Yes	to	LMPA	 No	
56	 	 No	 No	 No	
57	 Aortic	Coarctation	 No	 No	 No	
58	 TOF	 Yes	 No	 No	
59	 Truncus	Arteriosus	 Yes	 No	 No	
60	 	 No	 No	 No	
61	 TOF	 Yes	 No	 Yes:	Single:	1	from	DA	to	LMPA	
62	 TOF	 Yes	 No	 No	
63	 Truncus	Arteriosus	 Yes	 Yes	 No	
64	 	 No	 No	 No	
65	 TOF	 Yes	 No	 No	
66	 	 No	 No	 No	
67	 	 No	 No	 No	
68	 TOF	 Yes	 No	 No	
69	 No	 No	 No	 No	
70	 TOF	 Yes	 No	 No	
71	 PA	and	VSD	 Yes	 No	 No	
72	 	 No	 No	 No	
73	 	 No	 No	 No	
74	 TOF	Downs	 Yes	 No	 No	
75	 TOF	 Yes	 No	 No	
76	 	 No	 No	 No	
77	 TOF	 Yes	 No	 No	
78	 	 No	 No	 No	
79	 Truncus	Arteriosus	 Yes	 Yes	to	LMPA	 No	
80	 	 Yes	 No	 No	
81	 Truncus	Arteriosus	 No	 No	 No	
82	 TOF	 Yes	 Yes	to	LMPA	 Yes:	Multiple:	2	From	DA	to	RMPA	
83	 No	 No	 No	 No	
84	 TOF	 Yes	 Yes	to	LMPA	 No	
85	 TOF	 Yes	 No	 Yes:	Single:	1	from	Left	
Brachiocephalic/LSCA	to	LMPA		
86	 TOF	 Yes	 No	 No	
87	 DORV	 Yes	 No	 No	
88	 No	 No	 No	 No	
89	 Congenital	Rubella	 Yes	 Yes	to	LMPA	 No	
90	 Multiple	
Abnormalities	
Yes	 No	 Yes:	Multiple:	1	from	RSCA	to	
RULPA;	1	from	LSCA	to	LMPA	
91	 TOF	 Yes	 No	 No	
92	 	 No	 No	 No	
93	 TOF	 Yes	 Yes	to	LMPA	 No	
94	 	 Yes	 No	 No	
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95	 TOF	 Yes	 No	 No	
96	 TOF	 Yes	 Yes	to	LMPA	 Yes:	Multiple:	2	From	DA	to	RMPA	
97	 	 No	 No	 No	
98	 Truncus	Arteriosus	 Yes	 No	 No	
99	 TOF	 Yes	 Yes	to	LMPA	 No	
100	 PA	 Yes	 No	 No		
101	 	 No	 No	 No	
102	 	 Yes	 No	 No	
103	 TOF	 Yes	 No	 No	
104	 TOF	 Yes	 No	 Yes:	Single:	1	from	RSCA	to	Right	
Lung	
105	 	 No	 No	 No	
106	 Truncus	Arteriosus	 Yes	 No	 No	
107	 LPA	stenosis	 Yes	 No	 No	
108	 	 No	 No	 No	
109	 	 No	 No	 No	
110	 	 No	 No	 No	
111	 	 No	 No	 No	
112	 TOF	 Yes	 No	 No	
113	 TOF	 Yes	 No	 No	
114	 TOF	 Yes	 Yes	to	LMPA	 No	
115	 TOF	 Yes	 No	 No	
116	 	 No	 No	 No	
117	 	 No	 No	 No	
118	 TOF	 Yes	 No	 No	
119	 TOF	 Yes	 No	 No	
120	 TOF	 Yes	 No	 Yes:	Multiple:	1	from	RSCA	to	RUL-
PA;	1	from	LSCA	to	LMPA	
121	 TOF	 Yes	 No	 Yes:	Multiple:	1	from	Left	
Thyrocervical	Trunk	to	LMPA;	1	from	
AArch	to	LMPA;	1	from	
Infradiaphragmatic	arterial	system	
(?Coeliac	Trunk,	Left	Gastric	or	direct	
Aortic)	to	LMPA	
123	 	 No	 No	 No	
124	 	 No	 No	 No	
125	 TOF	 Yes	 No	 Yes:	Multiple:	1	from	LSCA;	1	from	
AArch;	1	from	Left	6th	Intercostal	
Artery	-	forming	an	arterial	plexus	
supplying	the	Left	Lung	
126	 	 No	 No	 No	
127	 TOF	 Yes	 No	 No	
128	 TOF	 Yes	 No	 Yes:	Multiple:	2	from	AArch	to	
plexus;	1	from	Right	Bronchial	Artery	
to	plexus;	1	from	Left	Inferior	
Bronchial	Artery	to	Plexus	-	to	Left	
Lung	
129	 PA	and	VSD	 Yes	 Yes	to	LMPA	 No	
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130	 TOF	 Yes	 No	 No	
131	 TOF	 Yes	 No	 No	
132	 TOF	 Yes	 No	 No	
133	 TOF	 Yes	 No	 No	
134	 TOF	 Yes	 No	 No	
135	 	 No	 No	 No	
136	 	 No	 No	 No	
137	 PA	and	AVSD	 Yes	 No	 No	
138	 TOF	 Yes	 No	 No	
139	 PA	and	VSD	 Yes	 No	 Yes:	Multiple:	3	from	DA	-	1	to	Left	
Interlobar	Artery;	1	to	LUL	
apicoposterior	segment;	1	to	LLL	
superior	segment	
140	 TOF	Downs	 Yes	 No	 No	
141	 TOF	 Yes	 No	 No	
142	 TOF	 Yes	 No	 No	
143	 	 No	 No	 No	
144	 	 No	 No	 No	
145	 	 No	 No	 No	
TOF	(tetralogy	of	Fallot);	PA	+	VSD	(pulmonary	atresia	and	ventricular	septal	defect);	LMPA	(left	main	
pulmonary	artery);	RMPA	(right	main	pulmonary	artery);	RUL-PA	(right	upper	lobe	pulmonary	artery);	RML-
PA	(right	middle	lobe	pulmonary	artery);	AArch	(aortic	arch);	DA	(descending	aorta);	LSCA	(left	subclavian	
artery);	RSCA	(right	subclavian	artery);	LLL	(Left	lower	lobe);	RUL	(right	upper	lobe);	RML	(right	middle	lobe);	
RLL	(right	lower	lobe)	
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Table	2.		Totals	and	Percentages	
	 No.	of	
Cases	
%	of	total	
MDCTAs	
%	of	
cases	
with	
PA/PS	
%	of	cases	
with	
Collateral	
Supply	
%	of	
cases	
with	
PDA		
%	of	
cases	
with	
SPC/s	
Total	Cardiac	MDCTAs	 145	 	 	 	 	 	
Total	without	PA/PS	 52	 37%	 	 	 	 	
Total	with	PA/PS	 93	 63%	 	 	 	 	
	 	 	 	 	 	 	
PA/PS	without	Collateral	
Supply	
62	 43%	 67%	 	 	 	
PA/PS	with	Collateral	
Supply	
31	 21%	 33%	 	 	 	
	 	 	 	 	 	 	
PDA	cases	Total	 17	 12%	 18%	 55%	 	 	
SPC/s	cases	Total	 19	 13%	 20%	 61%	 	 	
	 	 	 	 	 	 	
PDA	only	cases	 12	 8%	 13%	 39%	 	 	
SPC/s	only	cases	 14	 10%	 15%	 45%	 	 	
Both	SPCs	and	PDA	cases	 5	 3%	 5%	 16%	 29%	 26%	
	 	 	 	 	 	 	
Number	of	Cases	with	
single	SPC/s	
5	 3%	 5%	 16%	 	 26%	
Number	of	Cases	with	
Multiple	SPC/s	
14	 10%	 15%	 61%	 	 74%	
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Figure	1.	MDCTA	Cases	Totals	and	Percentages	
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MDCTA	Cases	
52	(37%)	
Without	PA	
93	(63%)	
With	TOF	
Spectrum	
Pulmonary	Atresia	
62	(67%)	
Without	Collateral	
Supply	
31	(33%)	
With	Collateral	
Supply	
19	(61%)	
With	SPCs	
17	(55%)	
With	PDA	
MDCTA	Cases	
5	(16%)	
With	Both	
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Figure	2.	MDCTA	Cases	With	and	Without	Pulmonary	Atresia/Stenosis	
	
Of	the	eligible	thoracic	cardiovascular	multi-detector	computed	tomography	angiography	
(MDCTA)	cases:	
	93/145	(63%)	were	found	to	have	pulmonary	atresia	(PA)	or	pulmonary	stenosis	(PS).	
	
MDCTA	Cases	
MDCTA	cases	with	
Pulmonary	Atresia/
Stenosis	
MDCTA	cases	without	
Pulmonary	Atresia/
Pulmonary	Stenosis	
93/145		
MDCTA	Cases	
=63%	
52/145		
MDCTA	Cases	
=37%	
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	Figure	3.	MDCTA	Cases	With	and	Without	Collateral	Supply	
	
Of	the	cases	with	PA/PS:	
31/93	(33%)	were	found	to	have	collateral	supply.		
	
MDCTA	Cases	
Pulmonary	Atresia/Stenosis	
without	Collateral	Supply	
Pulmonary	Atresia/Stenosis	with	
Collateral	Supply	
Cases	without	Pulmonary	
Atresia/Stenosis	
62/93		
Without	SPC/s		
and/or	PDA	
=	67%	
52/145		
MDCTA	Cases	
=	37%	
31/93		
With	SPC/s	
and/or	PDA	
=	33%	
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Figure	4.	MDCTA	Cases	With	SPC/s	and/or	PDA	
	
Of	the	cases	with	collateral	supply:		
19/31	(61%)	of	cases	were	found	to	have	systemic	to	pulmonary	collateral	arteries	
(SPC/s),	equating	to	19/93	(20%)	of	cases	with	PA/PS	and	19/145	(13%)	of	the	MDCTAs;		
17/31	(55%)	cases	were	found	to	have	a	PDA,	equating	to	17/93	(18%)	of	cases	with	
PA/PS	and	17/145	(12%)	of	the	MDCTAs;		
5/31	(16%)	were	found	to	have	both	a	PDA	and	SPC/s,	equating	to	5/17	(29%)	of	cases	
with	PDA,	5/19	(26%)	of	cases	with	SPC/s,	5/93	(5%)	of	cases	with	PA/PS	and	(5/145)	3%	
of	the	MDCTAs;	
14/31	(45%)	were	found	to	have	(SPC/s)	alone,	equating	to	14/93	(15%)	of	cases	with	
PA/PS	and	14/145	(10%)	of	the	MDCTAs;		
12/31	(39%)	of	cases	were	found	to	have	a	patent	ductus	arteriosus	alone,	equating	to	
12/93	(13%)	of	cases	with	PA/PS	and	12/145	(8%)	of	the	MDCTAs.		
MDCTA	Cases	
Pulmonary	Atresia/Stenosis	
without	Collateral	Supply	
Pulmonary	Atresia/Stenosis	with	
SPC/s	
Pulmonary	Atresia/Stenosis	with	
PDA	
Cases	without	Pulmonary	Atresia	
5	(16%)	
With	Both	
62/93		
TOF	Cases	
=	67%	
52/145		
MDCTA	Cases	
=	37%	
19/31		
SPC/s	
=	61%	
17/31		
PDA	
=	55%	
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Of	the	cases	with	SPC/s:	
5/19	(26%)	were	found	to	have	a	single	SPC,	equating	to	5/31	(16%)	of	cases	with	
collateral	supply,	5/93	(5%)	of	cases	with	PA/PS	and	5/145	(3%)	of	the	MDCTAs;		
14/19	(74%)	were	found	to	have	multiple	SPC/s,	equating	to	14/31	(45%)	of	cases	with	
collateral	supply,	14/93	(15%)	of	cases	with	PA/PS	and	14/145	(10%)	of	the	MDCTAs.	
	
Table	3.	Additional	information	
Additional	
Information	
	
No.	of	
Cases	
Breakdow
n	of	
Named	
Abn.	Cases	
%	of	
Total	
MDCTAs	
%	of	
Total	
Cases	
with	
PA/PS	
%	of	Total	
Cases	with	
Collateral	
Supply	
%	of	
Total	
Cases	
with	
PDA		
%	of	
Total	
Cases	
with	
SPC/s	
%	of	Total	
Cases	
with	both	
SPC/s	and	
PDA	
TOF	 61	 	 42%	 66%	 	 	 	 	
	 	 16	with	
Collateral	
Supply		
=		
26%	of	
TOF	
	 	 52%	 	 	 	
	 	 9	with	PDA		
=		
15%	of	
TOF	
	 	 29%	 53%	 	 	
	 	 10	with	
SPC/s		=		
16%	of	
TOF	
	 	 32%	 	 53%	 	
	 	 3	with	
both	PDA	
and	SPC/s	
=		
5%	of	TOF	
	 	 10%	 	 	 60%	
	 	 	 	 	 	 	 	 	
PA	+	VSD	 10	 	 7%	 11%	 	 	 	 	
	 	 5	with	
Collateral	
Supply		
=	
50%	of	PA	
+	VSD	
	 	 16%	 	 	 	
	 	 1	with	PDA	
=	
10%	of	PA	
	 	 3%	 6%	 	 	
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+	VSD	
	 	 4	with	
SPC/s	
=	
40%	of	PA	
+	VSD	
	 	 13%	 	 21%	 	
	 	 0	with	
both	PDA	
and	SPC/s	
	 	 0%	 	 	 0%	
	 	 	 	 	 	 	 	 	
Truncus	
Arteriosus	
(TA)	
8	 	 6%	 9%	 	 	 	 	
	 	 2	with	
Collateral	
Supply	
=	
25%	of	TA	
	 	 6%	 	 	 	
	 	 2	with	PDA	
=	
25	%	of	TA	
	 	 6%	 12%	 	 	
	 	 0	with	
SPC/s	
	 	 	 	 0%	 	
	 	 0	with	
both	PDA	
and	SPC/s	
	 	 	 	 	 0%	
	 	 	 	 	 	 	 	 	
Congenital	
Rubella	(CR)	
2	 	 1%	 2%	 	 	 	 	
	 	 2	with	
Collateral	
Supply	
=	
100%	of	
CR	
	 	 6%	 	 	 	
	 	 2	with	PDA	
=	
100%	of	
CR	
	 	 6%	 12%	 	 	
	 	 0	with	
SPC/s	
	 	 	 	 0%	 	
	 	 0	with	
both	PDA	
and	SPC/s	
	 	 	 	 	 0%	
	 	 	 	 	 	 	 	 	
Di	George	
(DG)	
1	 	 1%	 1%	 	 	 	 	
	 	 1	with	
Collateral	
Supply	
=	
100%	of	
DG	
	 	 3%	 	 	 	
	 	 1	with	PDA	
=	
	 	 3%	 6%	 	 	
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100%	of	
DG	
	 	 1	with	
SPC/s	
=	
100%	of	
DG	
	 	 3%	 	 5%	 	
	 	 1	with	
both	PDA	
and	SPC/s	
=		
100%	of	
DG	
	 	 3%	 	 	 20%	
	 	 	 	 	 	 	 	 	
Dextrocardia	
with	Right-
Sided	
Isomerism	
(DwRSI)	
1	 	 1%	 1%	 	 	 	 	
	 	 1	with	
Collateral	
Supply	
=	
100%	of	
DwRSI	
	 	 3%	 	 	 	
	 	 1	with	PDA	
=	
100%	of	
DwRSI	
	 	 3%	 6%	 	 	
	 	 0	with	
SPC/s	
	 	 	 	 0%	 	
	 	 0	with	
both	PDA	
and	SPC/s	
	 	 	 	 	 0%	
	 	 	 	 	 	 	 	 	
Absent	
Pulmonary	
Valve	
Syndrome	
(APVS)	
1	 	 1%	 1%	 	 	 	 	
	 	 1	with	
Collateral	
Supply	
=	
100%	of	
APVS	
	 	 3%	 	 	 	
	 	 0	with	PDA	 	 	 	 0%	 	 	
	 	 1	with	
SPC/s	
=	
100%	of	
APVS	
	 	 3%	 	 5%	 	
	 	 0	with	
both	PDA	
and	SPC/s	
	 	 	 	 	 0%	
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Of	the	MDCTAs:	
61/145	(42%)	were	found	to	have	tetralogy	of	Fallot	(TOF),	equating	to	61/93	(66%)	of	
cases	with	PA/PS.		
10/145	(7%)	were	found	to	have	pulmonary	atresia	and	ventricular	septal	defect	(PA	+	
VSD)	equating	to	10/93	(11%)	of	cases	with	PA/PS.		
8/145	(6%)	were	found	to	have	truncus	arteriosus	(TA),	equating	to	8/93	(9%)	of	cases	
with	PA/PS.		
2/145	(1%)	were	found	to	have	congenital	rubella	(CR),	equating	to	2/93	(2%)	of	cases	
with	PA/PS.		
1/145	(1%)	was	found	to	have	Di	George	(DG),	equating	to	1/93	(1%)	of	cases	with	PA/PS.		
1/145	(1%)	was	found	to	have	dextrocardia	with	right-sided	isomerism	(DwRSI),	equating	
to	1/93	(1%)	of	cases	with	PA/PS.		
1/195	(1%)	was	found	to	have	absent	pulmonary	valve	syndrome	(APVS),	equating	to	
1/93	(1%)	of	cases	with	PA/PS.		
	
Of	the	cases	with	TOF:	
16/61	(26%)	were	found	to	have	collateral	supply,	equating	to	16/31	(52%)	of	the	total	
number	of	cases	with	collateral	supply;		
9/61	(15%)	were	found	to	have	a	PDA,	equating	to	9/31	(29%)	of	the	total	number	of	
cases	with	collateral	supply,	9/17	(53%)	of	the	total	number	of	cases	with	PDA;	
10/61	(16%)	were	found	to	have	SPC/s,	equating	to	10/31	(32%)	of	the	total	number	of	
cases	with	collateral	supply,	10/19	(53%)	of	the	total	number	of	cases	with	SPC/s;	
3/61	(5%)	were	found	to	have	both	a	PDA	and	SPC/s,	equating	to	3/31	(10%)	of	the	total	
number	of	cases	with	collateral	supply,	3/5	(60%)	of	cases	with	both	PDA	and	SPC/s.		
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Of	the	cases	with	PA	+	VSD:	
5/10	(50%)	were	found	to	have	collateral	supply,	equating	to	5/31	(16%)	of	the	total	
number	of	cases	with	collateral	supply;		
1/10	(1%)	was	found	to	have	a	PDA,	equating	to	1/31	(3%)	of	the	total	number	of	cases	
with	collateral	supply,	1/17	(6%)	of	the	total	number	of	cases	with	PDA	and	1/19	(10%)	of	
cases	with	PA	+	VSD;		
4/10	(40%	)	were	found	to	have	SPC/s,	equating	to	4/31	(13%)	of	the	total	number	of	
cases	with	collateral	supply,	4/19	(21%)	of	the	total	number	of	cases	with	SPC/s;		
0/10	(0%)	were	found	to	have	both	a	PDA	and	SPC/s,	equating	to	0/31	(0%)	of	the	total	
number	of	cases	with	collateral	supply	and	0/5	(0%)	of	cases	with	both	PDA	and	SPC/s.			
	
Of	the	cases	with	TA:	
2/8	(25%)	were	found	to	have	collateral	supply,	equating	to	2/31	(6%)	of	the	total	number	
of	cases	with	collateral	supply;		
2/8	(25%)	were	found	to	have	a	PDA,	equating	to	2/31	(6%)	of	the	total	number	of	cases	
with	collateral	supply,	2/17	(12%)	of	the	total	number	of	cases	with	PDA;		
0/8	were	found	to	have	SPC/s,	equating	to	0/31	(0%)	of	the	total	number	of	cases	with	
collateral	supply,	0/19	(0%)	of	the	total	number	of	cases	with	SPC/s;	
0/8	were	found	to	have	both	a	PDA	and	SPC/s,	equating	to	0/31	(0%)	of	the	total	number	
of	cases	with	collateral	supply,	0/5	(0%)	of	cases	with	both	PDA	and	SPC/s.			
	
Of	the	cases	with	CR:	
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	2/2	(100%)	were	found	to	have	collateral	supply,	equating	to	2/31	(6%)	of	the	total	
number	of	cases	with	collateral	supply;		
2/2	(100%)	were	found	to	have	a	PDA,	equating	to	2/31	(6%)	of	the	total	number	of	cases	
with	collateral	supply	and	2/17	(12%)	of	the	total	number	of	cases	with	PDA;		
0/2	(0%)	were	found	to	have	SPC/s,	equating	to	0/31	(0%)	of	the	total	number	of	cases	
with	collateral	supply,	0/19	(0%)	of	the	total	number	of	cases	with	SPC/s;		
0/2	(0%)	were	found	to	have	both	a	PDA	and	SPC/s,	equating	to	0/31	(0%)	of	the	total	
number	of	cases	with	collateral	supply,	0/5	(0%)	of	cases	with	both	PDA	and	SPC/s.			
	
Of	the	cases	with	DG:		
1/1	(100%)	was	found	to	have	collateral	supply,	equating	to	1/31	(3%)	of	the	total	
number	of	cases	with	collateral	supply;		
1/1	was	found	to	have	a	PDA,	equating	to	1/31	(3%)	of	the	total	number	of	cases	with	
collateral	supply,	1/17	(6%)	of	the	total	number	of	cases	with	PDA	and	1/1	(100%)	of	
cases	with	DG;		
1/1	was	found	to	have	SPC/s,	equating	to	1/31	(3%)	of	the	total	number	of	cases	with	
collateral	supply	and	1/19	(5%)	of	the	total	number	of	cases	with	SPC/s;		
1/1	(100%)	was	found	to	have	both	a	PDA	and	SPC/s,	equating	to	1/31	(3%)	of	the	total	
number	of	cases	with	collateral	supply,	1/5	(20%)	of	cases	with	both	PDA	and	SPC/s.			
	
Of	the	cases	with	DwRSI:		
1/1	(100%)	was	found	to	have	collateral	supply,	equating	to	1/31	(3%)	of	the	total	
number	of	cases	with	collateral	supply;		
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1/1	(100%)	was	found	to	have	a	PDA,	equating	to	1/31	(3%)	of	the	total	number	of	cases	
with	collateral	supply	and	1/17	(6%)	of	the	total	number	of	cases	with	PDA;		
0/1	(0%)	were	found	to	have	SPC/s,	equating	to	0/31	(0%)	of	the	total	number	of	cases	
with	collateral	supply,	0/19	(0%)	of	the	total	number	of	cases	with	SPC/s;		
0/1	(0%)	were	found	to	have	both	a	PDA	and	SPC/s,	equating	to	0/31	(0%)	of	the	total	
number	of	cases	with	collateral	supply	and	(0/5)	0%	of	cases	with	both	PDA	and	SPC/s.			
	
Of	the	cases	with	APVS:		
1/1	(100%)	was	found	to	have	collateral	supply,	equating	to	1/31	(3%)	of	the	total	
number	of	cases	with	collateral	supply;		
0/1	(0%)	were	found	to	have	a	PDA,	equating	to	0/31	(0%)	of	the	total	number	of	cases	
with	collateral	supply,	0/17	(0%)	of	the	total	number	of	cases	with;		
1/1	(100%)	was	found	to	have	SPC/s,	equating	to	1/31	(3%)	of	the	total	number	of	cases	
with	collateral	supply	and	1/19	(5%)	of	the	total	number	of	cases	with	SPC/s;		
0/1	(0%)	were	found	to	have	both	a	PDA	and	SPC/s,	equating	to	0/31	(0%)	of	the	total	
number	of	cases	with	collateral	supply,	0/5	(0%)	of	cases	with	both	PDA	and	SPC/s.	
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Table	4.	Named	Artery	of	Origin	
Named	Artery	of	
Origin	
Total	number	of	
Cases	with	
SPC/s	
originating	from	
the	Named	
Artery	of	Origin	
Total	number	
of	SPC/s	
originating	
from	the	
Named	Artery	
of	Origin	
%	of	the	
Total	
Number	
of	SPC/s	
Number	of	
Cases	with	
Multiple	SPC/s	
originating	
from	the	same	
Named	Artery	
of	Origin	
%	of	Named	
Artery	of	Origin	
with	multiple	
SPC/s	
Ascending	Aorta	
(AA)	
0	 0	 0%	 0	 0%	
Aortic	Arch	(AArch)	 6	 7	 17%	 1	 17%	
Descending	Aorta	
(DA)	
9	 17	 41%	 6	 67%	
Right	Subclavian	
Artery	(RSCA)	
4	 4	 10%	 0	 0%	
Left	Subclavian	
Artery	(LSCA)	
6	 6	 15%	 0	 0%	
Right	Vertebral	
Artery	(RVA)	
1	 1	 2%	 0	 0%	
Left	Thyrocervical	
Trunk	(LTCT)	
1	 1	 2%	 0	 0%	
Intercostal	Artery	 1	 1	 2%	 0	 0%	
Right	Bronchial	
Artery		(RBA)	
1	 1	 2%	 0	 0%	
Left	Inferior	
Bronchial	Artery	
(LIBA)	
1	 1	 2%	 0	 0%	
Infradiaphragmatic	
Artery	
2	 2	 5%	 0	 0%	
	 	 	 	 	 	
Total	Number	 	 41	 	 7	 	
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Figure	5.	Named	Artery	of	Origin	as	a	Percentage	of	the	Total	Number	of	SPC/s	
	
A	total	of	41	SPC/s	were	found.		
Of	the	cases	with	SPC/s:		
	
7/41	(17%)	were	found	to	have	multiple	SPC/s	originating	from	the	same	named	artery	of	
origin.		
	
6/19	(32%)	of	cases	were	found	to	have	SPC/s	originating	from	the	aortic	arch	(AArch),	of	
which	1/19	(5%)	of	cases	were	found	to	have	multiple	SPC/s	originating	from	the	AArch,	
equating	to	1/6	(17%)	of	cases	with	AArch	origin	SPC/s.		
The	total	number	of	AArch	origin	SPC/s	was	found	to	be	7/41	(17%)	of	the	total	number	
of	SPC/s.		
Named	Artery	of	Origin	as	a	Percentage	of	the	Total	Number	of	SPC/s	
Aor$c	Arch	(AArch)	
Descending	Aorta	(DA)	
Right	Subclavian	Artery	(RSCA)	
Le<	Subclavian	Artery	(LSCA)	
Infradiaphragma$c	
Right	Vertebral	Artery	
Le<	Thyrocervical	Trunk	
Intercostal	Artery	
Right	Bronchial	Artery	
Le<	Inferior	Bronchial	Artery	
7	=	17%	
AArch	
17	=	41%	
DA	4	=	10%	
RSCA	
	
6	=	15%	
LSCA	
2	=	5%	
Infradiaphragma$c	
There	were	41	SPCs	in	total	
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9/19	(47%)	of	cases	were	found	to	have	SPC/s	originating	from	the	descending	aorta	(DA),	
of	which	6/19	(32%)	of	cases	were	found	to	have	multiple	SPC/s	originating	from	the	DA,	
equating	to	6/9	(67%)	of	cases	with	DA	origin	SPC/s.		
The	total	number	of	DA	origin	SPC/s	was	found	to	be	17/41	(41%)	of	the	total	number	of	
SPC/s.		
4/19	(21%)	of	cases	were	found	to	have	SPC/s	originating	from	the	right	subclavian	artery	
(RSCA),	of	which	0/19	(0%)	of	cases	were	found	to	have	multiple	SPC/s	originating	from	
the	RSCA,	equating	to	0/4	(0%)	of	cases	with	RSCA	origin	SPC/s.		
The	total	number	of	RSCA	origin	SPC/s	was	found	to	be	4/41	(10%)	of	the	total	number	of	
SPC/s.		
6/19	(32%)	of	cases	were	found	to	have	SPC/s	originating	from	the	left	subclavian	artery	
(LSCA),	of	which	0/19	(0%)	of	cases	were	found	to	have	multiple	SPC/s	originating	from	
the	LSCA,	equating	to	0/6	(0%)	of	cases	with	RSCA	origin	SPC/s.		
The	total	number	of	LSCA	origin	SPC/s	was	found	to	be	6/41	(15%)	of	the	total	number	of	
SPC/s.		
1/19	(5%)	of	case	were	found	to	have	SPC/s	originating	from	the	right	vertebral	artery	
(RVA),	of	which	0/19	(0%)	of	cases	were	found	to	have	multiple	SPC/s	originating	from	the	
RVA,	equating	to	0/1	(0%)	of	cases	with	RVA	origin	SPC/s.		
The	total	number	of	RVA	origin	SPC/s	was	found	to	be	1/41	(2%)	of	the	total	number	of	
SPC/s.		
1/19	(5%)	of	cases	were	found	to	have	SPC/s	originating	from	the	left	thyrocervical	trunk	
(LTCT),	of	which	0/19	(0%)	of	cases	were	found	to	have	multiple	SPC/s	originating	from	
the	LTCT,	equating	to	0/1	(0%)	of	cases	with	LTCT	origin	SPC/s.		
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The	total	number	of	LTCT	origin	SPC/s	was	found	to	be	1/41	(2%)	of	the	total	number	of	
SPC/s.		
1/19	(5%)	of	cases	were	found	to	have	SPC/s	originating	from	the	intercostal	artery	(IA),	
of	which	0/19	(0%)	of	cases	were	found	to	have	multiple	SPC/s	originating	from	the	IA,	
equating	to	0/1	(0%)	of	cases	with	IA	origin	SPC/s.		
The	total	number	of	IA	origin	SPC/s	was	found	to	be	1/41	(2%)	of	the	total	number	of	
SPC/s.		
1/19	(5%)	case	was	found	to	have	SPC/s	originating	from	the	right	bronchial	artery	(RBA),	
of	which	0/19	(0%)	of	cases	were	found	to	have	multiple	SPC/s	originating	from	the	RBA,	
equating	to	0/1	(0%)	of	cases	with	RBA	origin	SPC/s.		
The	total	number	of	RBA	origin	SPC/s	was	found	to	be	1/41	(2%)	of	the	total	number	of	
SPC/s.		
1/19	(5%)	of	cases	were	found	to	have	SPC/s	originating	from	the	left	inferior	bronchial	
artery	(LIBA),	of	which	0/19	(0%)	of	cases	were	found	to	have	multiple	SPC/s	originating	
from	the	LIBA,	equating	to	0/1	(0%)	of	cases	with	LIBA	origin	SPC/s.	
The	total	number	of	LIBA	origin	SPC/s	was	found	to	be	1/41	(2%)	of	the	total	number	of	
SPC/s.		
2/19	(11%)	of	cases	were	found	to	have	SPC/s	originating	from	an	infradiaphragmatic	
origin,	of	which	0/19	(0%)	of	cases	were	found	to	have	multiple	SPC/s	originating	from	
infradiaphragmatic	origins,	equating	to	0/2	(0%)	of	cases	with	infradiaphragmatic	origin	
SPC/s.		
The	total	number	of	infradiaphragmatic	origin	SPC/s	was	found	to	be	2/41	(5%)	of	the	
total	number	of	SPC/s.		
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8.	Discussion	
8.1.	Results	in	context		
As	discussed,	accurate	and	comprehensive	knowledge	of	the	prevailing	vascular	network	
supplying	the	lungs,	including	the	native	pulmonary	vasculature	and	the	presence	and	
pattern	of	systemic	to	pulmonary	collateral	supply,	is	critical	to	the	management	of	
pulmonary	atresia	(PA)	and	pulmonary	stenosis	(PS).	The	timing	and	approach	to	surgical	
repair	is	dependent	on	this	information.		
	
In	this	study,	33%	of	the	cases	found	to	have	PA/PS	were	also	found	to	have	systemic	to	
pulmonary	collateral	supply	in	the	form	of	a	patent	ductus	arteriosus	(PDA),	systemic	to	
pulmonary	collateral	artery/s	(SPC/s)	or	both.	Such	a	high	prevalence	of	systemic	to	
pulmonary	collateral	supply	in	PA/PS	emphasises	the	importance	of	having	a	diligent	and	
systematic	method	of	search	for	such	vessels.		
	
The	prevalence	of	SPC/s	at	20%	of	cases	with	PA/PS,	and	at	61%	of	cases	with	systemic	to	
pulmonary	collateral	supply,	is	greater	than	the	prevalence	of	a	PDA	at	18%	and	55%	
respectively.	The	relatively	high	rate	of	occurrence	and	known	variability	in	origin	and	
destination	of	SPC/s	also	emphasises	the	importance	of	having	a	diligent	and	systematic	
method	of	search.		
	
However,	if	a	PDA	is	considered	to	be	a	specific	SPC/s,	then	the	case	prevalence	of	a	PDA	
at	17	cases	is	nearly	double	that	of	any	other	specific	SPC/s	prevalence,	the	next	being	
descending	aorta	originated	SPC/s	at	9	cases.		In	terms	of	systemic	to	pulmonary	
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collateral	vessel	prevalence,	the	number	of	PDAs	is	equitable	to	SPC/s	originating	from	
the	descending	aorta	at	17	cases	each.		In	other	words	a	PDA	is	first	amongst	SPC/s.		
	
Furthermore,	in	this	study,	16%	of	cases	with	systemic	to	pulmonary	collateral	supply	
were	found	to	have	both	a	PDA	and	SPC/s	and	74%	of	cases	with	SPC/s	were	found	to	
have	multiple	SPC/s,	again	emphasising	the	importance	of	having	a	diligent	and	
systematic	method	of	search	for	such	vessels.	
	
Key	to	developing	a	systematic	method	of	search	is	knowledge	of	which	systemic	arteries	
give	origin	to	systemic	to	pulmonary	collateral	vessels	and	with	what	frequency.		
	
By	definition	a	PDA	arises	from	the	aortic	arch	(AArch)	and	communicates	with	the	
pulmonary	trunk	(PT)	superiorly	at	the	origin	of	the	left	main	pulmonary	artery	(LMPA).	
This	is	not	surprising	given	that	the	ductus	arteriosus	and	LMPA	share	a	common	
embryological	origin	from	the	left	6th	primitive	aortic	arch.	Therefore,	any	persistent	
communication	between	the	AArch	and	the	PT	may	be	regarded	as	a	PDA.		In	right-sided	
isomerism,	however,	the	PDA	originates	from	the	right-sided	aortic	arch	and	
communicates	with	the	PT	superiorly	at	the	origin	of	the	right	main	pulmonary	artery	
(RMPA).	One	such	case	is	documented	in	this	study.	Rarely,	bilateral	PDAs	are	known	to	
occur.	A	PDA	may	have	many	morphological	appearances	for	which	there	have	been	
several	proposed	classification	systems.		
	
The	search	for	SPC/s	is	challenging	due	to	their	variability	in	origin	and	destination.	In	this	
study,	the	greatest	number	of	SPC/s	originated	from	the	descending	aorta	(DA)	at	41%	of	
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the	total	number	of	SPC/s	identified,	followed	by	the	aortic	arch	(AArch)	at	17%,	the	left	
subclavian	artery	(LSCA)	at	15%,	the	right	subclavian	artery	(RSCA)	at	10%,	
infradiaphragmatic	arteries	at	5%	and	the	right	vertebral	artery,	left	thyrocervical	trunk,	
an	intercostal	artery,	right	bronchial	artery	and	left	inferior	bronchial	artery	at	2%	a	piece.		
	
Of	note,	no	SPC/s	originated	from	the	ascending	aorta	(AA)	and	the	pulmonary	trunk	(PT)	
received	no	SPC/s	(apart	from	PDA).	Again,	embryological	development	makes	this	an	
unsurprising	result	as	both	arise	from	the	truncus	arteriosus	and	not	the	primitive	aortic	
arches.		
8.2.	Pitfalls	
Variability	in	bronchial	artery	morphology	is	well	described	and	the	Cauldwell	
classification	system	is	commonly	sited.		Up	to	80%	of	bronchial	arteries	arise	from	the	
descending	aorta	at	the	T5-T6	level.	In	this	study,	several	cases	with	pulmonary	atresia	or	
pulmonary	stenosis	were	found	to	have	dilated,	ectatic	bronchial	arteries	augmenting	
pulmonary	blood	supply.	These	bronchial	arteries	might	easily	be	misinterpreted	to	be	
SPC/s	and	caution	must	be	exercised	to	not	label	SPC/s	in	this	region	unless	definite	
communication	with	the	pulmonary	arterial	circulation	is	identified.	It	is	also	important	to	
distinguish	SPC/s	from	the	artery	of	Adamkiewicz	as	ligation	or	“unifocalization”	of	this	
artery	would	likely	have	catastrophic	neurological	consequences.	
	
Specific	infradiaphragmatic	vessels	of	SPC/s	origins	were	not	visualised	due	to	
predetermined	setting	of	the	inferior	scan	limit	to	reduce	radiation	burden.	The	accurate	
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depiction	of	the	infradiaphragmatic	origin	SPC/s	may	therefore	justify	the	dose	penalty	
incurred	by	increasing	the	field	of	view.		
	
8.3.	Limitations	of	the	current	study	
This	study’s	sensitivity	and	specificity	are	dependent	on	the	acquisition,	display	and	
interpretation	of	images.	Whilst	the	hardware,	software,	acquisition	technique	and	image	
display	fall	comfortably	within	international	standards,	improvements	such	as	a	more	
advanced,	higher	slice	capability	CT	scanner,	more	advanced	software	and	the	use	of	
prospective	ECG-synchronised	MDCTA	acquisition	methods	to	diminish	cardiac	motion	
artefact	may	further	positively	influence	the	quality	of	results.		
	
Streak	artefact	generated	by	contrast	within	the	subclavian	vein	on	the	side	of	contrast	
administration	from	upper	limb	cannulation	may	have	obscured	undiagnosed	SPC/s.	
Exclusive	use	of	foot	veins	for	the	administration	of	contrast	would	alleviate	this	
limitation.	
	
In	addition,	whilst	the	reading	of	this	study’s	MDCTAs	was	done	by	both	a	diagnostic	
radiology	consultant	and	a	senior	diagnostic	radiology	registrar,	on	two	different	
occasions	with	temporal	separation	of	at	least	3	months,	and	routine	co-interpretation	of	
the	images	with	the	involved	cardiologist	was	performed,	involvement	of	further	readers	
might	positively	influence	the	quality	of	results.				
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The	data	collection	period	spanned	4	years	at	RCWMCH,	the	largest	dedicated	paediatric	
hospital	in	Southern	Africa,	however	a	longer	time	period	of	collection	and	the	inclusion	
of	other	paediatric	imaging	centres	might	increase	the	size	of	the	data	set	and	positively	
influence	the	quality	of	results.		
8.4.	Future	applications		
Information	from	this	study	could	be	utilised	to	aid	the	investigation	of	whether	specific	
sites	and	degrees	of	PA/PS	correlate	with	specific	patterns	of	systemic	to	pulmonary	
circulation	collateral	supply.		
	
	
9.	Conclusion	
	
In	light	of	this	study’s	results,	any	MDCTA	performed	that	demonstrates	pulmonary	
atresia	or	pulmonary	stenosis	should	be	closely	evaluated	for	a	patent	ductus	arteriosus	
(PDA)	and	systemic	to	pulmonary	collateral	arteries	(SPC/s).	The	results	indicate	that	the	
recommended	pattern	of	search	should	be	for	a	PDA	first,	then	for	SPC/s	originating	from	
the	descending	aorta	(DA),	aortic	arch	(AArch),	left	subclavian	artery	(LSCA)	and	right	
subclavian	artery	(RSCA).	Given,	in	this	study	and	published	literature,	that	SPC/s	have	
been	found	to	arise	from	a	variety	of	smaller	vessels	such	as	vertebral,	bronchial	and	
intercostal	arteries	as	well	as	infradiaphragmatic	sources	and	hence	no	systemic	artery	
can	be	neglected.	The	frequency	of	infradiaphragmatic	origin	SPC/s	may	justify	the	dose	
penalty	incurred	by	increasing	the	field	of	view.		
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Knowing	that	comprehensive	knowledge	of	the	alternative	vascular	network	supplying	
the	lungs	is	critical	to	the	management	of	pulmonary	atresia	and	pulmonary	stenosis	
advocates	the	development	of	an	accurate,	informative	and	standardised	nomenclature	
system	for	systemic	to	pulmonary	collateral	arteries.	In	this	study,	40%	of	SPC/s	were	
found	to	originate	from	arteries	other	than	the	aorta,	which	strongly	supports	using	the	
term	systemic	to	pulmonary	collateral	artery/s	(SPC/s)	and	not	major	aortopulmonary	
collateral	artery/s	(MAPCA/s)	as	a	general	term.	The	large	variability	in	location	of	SPC/s	
makes	a	classification	system	impractical	and	encourages	descriptive	characterization,	the	
fundamental	integrals	of	which	are	origin	and	destination.	For	example,	descending	aorta	
to	left	main	pulmonary	artery	(DA	to	LMPA),	or	right	subclavian	artery	to	right	upper	lobe	
pulmonary	artery	(RSCA	to	RUL-PA),	or,	in	slightly	more	complex	situations,	aortic	arch	
with	a	branch	to	the	right	main	pulmonary	artery	and	a	branch	to	the	right	lower	lobe	
(AArch	to	RMPA	and	RLL).	Whilst	descriptive,	this	format	fulfils	the	requirements	of	being	
accurate,	informative	and	standardised.		
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11.	Appendices	
Appendix	1	-	see	5.3.1.1.	Multi-detector	Computed	Tomography	Scanner	
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Appendix	2	-	see	5.3.1.2.	Workspace	
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Appendix	3	-	see	5.3.1.3.	CT	Injection	System	
	
Appendix	4	–	see	5.3.1.4.	Reporting	Station	
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Appendix	5	–	see	5.4	Data	Collection	
Cardiac	CTA	Inclusion	Cases	
Case	 Recognisable	Pattern	of	
Congenital	Heart	Disease	
(Type	or	No)	
Pulmonary	
Arterial	System	
Atresia	(Yes	or	
No)	
Patent	Ductus	
Arteriosus	(Yes	
or	No)	
Systemic	to	Pulmonary	
Collateral	Artery	(Origin/s	
or	No)	
		 		 		 		 		
1	 ?	 ?	 ?	 ?	
2	 ?	 ?	 ?	 ?	
3	 ?	 ?	 ?	 ?	
4	 ?	 ?	 ?	 ?	
5	 ?	 ?	 ?	 ?	
Etc.	 Etc.	 Etc.	 Etc.	 Etc.	
	
Appendix	6	–	see	5.4	Data	Collection	
Totals	and	Percentages	
	 No.	of	
Cases	
%	of	total	
CTAs	
%	of	
cases	
with	PA	
%	of	cases	
with	
Collateral	
Supply	
%	of	
cases	
with	
PDA		
%	of	
cases	
with	SPCs	
Total	Cardiac	CTAs	 ?	 	 	 	 	 	
Total	without	PA	 ?	 ?%	 	 	 	 	
Total	with	PA	 ?	 ?%	 	 	 	 	
	 	 	 	 	 	 	
PA	without	Collateral	
Supply	
?	 ?%	 ?%	 	 	 	
PA	with	Collateral	Supply	 ?	 ?%	 ?%	 	 	 	
	 	 	 	 	 	 	
PDA	cases	Total	 ?	 ?%	 ?%	 ?%	 	 	
SPC	cases	Total	 ?	 ?%	 ?%	 ?%	 	 	
	 	 	 	 	 	 	
PDA	only	cases	 ?	 ?%	 ?%	 ?%	 	 	
SPCs	only	cases	 ?	 ?%	 ?%	 ?%	 	 	
Both	SPCs	and	PDA	cases	 ?	 ?%	 ?%	 ?%	 ?%	 ?%	
	 	 	 	 	 	 	
Number	of	Cases	with	
single	SPC	
?	 ?%	 ?%	 ?%	 	 ?%	
Number	of	Cases	with	
Multiple	SPCs	
?	 ?%	 ?%	 ?%	 	 ?%	
	
	
76	
	
Appendix	7	–	see	5.4	Data	Collection	
Recognisable	Pattern	of	Congenital	Cardiac	Disease	(CHD)	
Recognisable	
Pattern	of	
CHD		
No.	
of	
Cases	
Breakdown	of	
Named	
Abnormality	
Cases	
%	of	total	
CTAs	
%	of	
Total	
Cases	
with	
PA	
%	of	
Total	
Cases	
with	
Collater
al	
Supply	
%	of	
Total	
Cases	
with	
PDA		
%	of	
total	
cases	
with	
SPC/s	
%	of	Total	
Cases	
with	both	
SPC/s	and	
PDAs	
?	 ?	 	 ?%	 ?%	 	 	 	 	
	 	 ?	with	
Collateral	
Supply	=	?	of	
TOF	
	 	 ?%	 	 	 	
	 	 ?	with	PDA	=	
?%	of	TOF	
	 	 ?%	 ?%	 	 	
	 	 ?	with	SPC/s	=	
?%	of	TOF	
	 	 ?%	 	 ?%	 	
	 	 ?	with	both	
PDA	and	SPC/s	
=	?%	of	TOF	
	 	 ?%	 	 	 ?%	
	 	 	 	 	 	 	 	 	
?	 ?	 	 ?%	 ?%	 	 	 	 	
	 	 ?	with	
Collateral	
Supply	=	?	of	
TOF	
	 	 ?%	 	 	 	
	 	 ?	with	PDA	=	
?%	of	TOF	
	 	 ?%	 ?%	 	 	
	 	 ?	with	SPC/s	=	
?%	of	TOF	
	 	 ?%	 	 ?%	 	
	 	 ?	with	both	
PDA	and	SPC/s	
=	?%	of	TOF	
	 	 ?%	 	 	 ?%	
	 	 	 	 	 	 	 	 	
Etc.	 	 Etc.	 Etc.	 Etc.	 Etc.	 Etc.	 Etc.	 Etc.	
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Appendix	8	–	see	5.4	Data	Collection	
Named	Artery	of	Origin	
Named	Artery	of	
Origin	
Total	number	of	
Cases	with	SPCs	
originating	from	
the	Named	
Artery	of	Origin	
Total	number	
of	SPC/s	
originating	
from	the	
Named	Artery	
of	Origin	
%	of	the	
Total	
Number	
of	SPC/s	
Number	of	Cases	
with	Multiple	SPCs	
originating	from	
the	same	Named	
Artery	of	Origin	
%	of	
Named	
Artery	of	
Origin	
with	
multiple	
SPC/s	
?	 ?	 ?	 ?	 ?	 ?	
?	 ?	 ?	 ?	 ?	 ?	
?	 ?	 ?	 ?	 ?	 ?	
?	 ?	 ?	 ?	 ?	 ?	
?	 ?	 ?	 ?	 ?	 ?	
Etc.	 Etc.	 Etc.	 Etc.	 Etc.	 Etc.	
	 	 	 	 	 	
Total	Number	 	 ?	 	 ?	 	
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Appendix	9	–	Departmental	Research	Committee	Approval	
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Appendix	9	–	Human	Research	Ethics	Committee	Approval	
	
